T1	tradename 115 123	TAXOTERE
T3	tradename 186 195	TAXOTERE.
T5	tradename 207 215	TAXOTERE
T7	activeingredient 217 227	docetaxel)
T9	routeofadministration 251 262	Intravenous
T11	routeofadministration 273 276	IV)
T13	fdaapprovaldate 301 305	1996
T15	adversereaction 337 349	TOXIC DEATHS
T17	adversereaction 351 365	HEPATOTOXICITY
T19	adversereaction 367 378	NEUTROPENIA
T21	adversereaction 380 406	HYPERSENSITIVITY REACTIONS
T23	adversereaction 412 427	FLUID RETENTION
T25	adversereaction 516 525	mortality
T27	adversereaction 541 564	abnormal liver function
T29	indication 604 609	NSCLC
T31	tradename 653 661	TAXOTERE
T33	dose 665 674	100 mg/m2
T35	adversereaction 1076 1087	neutropenia
T37	adversereaction 1110 1126	hypersensitivity
T39	adversereaction 1154 1165	anaphylaxis
T41	tradename 1304 1312	TAXOTERE
T43	adversereaction 1409 1435	hypersensitivity reactions
T45	tradename 1439 1447	TAXOTERE
T47	inactiveingredient 1476 1490	polysorbate 80
T49	adversereaction 1513 1528	fluid retention
T51	tradename 1849 1857	TAXOTERE
T53	chemoclass 1863 1884	microtubule inhibitor
T55	indication 1911 1924	Breast Cancer
T57	co-administereddrug 2019 2030	doxorubicin
T59	co-administereddrug 2035 2051	cyclophosphamide
T61	indication 2131 2166	Non-Small Cell Lung Cancer (NSCLC):
T63	indication 2215 2220	NSCLC
T65	co-administereddrug 2262 2271	cisplatin
T67	indication 2331 2336	NSCLC
T69	indication 2364 2406	Hormone Refractory Prostate Cancer (HRPC):
T71	co-administereddrug 2412 2422	prednisone
T73	indication 2479 2494	prostate cancer
T75	indication 2523 2551	Gastric Adenocarcinoma (GC):
T77	co-administereddrug 2557 2566	cisplatin
T79	co-administereddrug 2571 2583	fluorouracil
T81	indication 2680 2740	Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN):
T83	co-administereddrug 2746 2755	cisplatin
T85	co-administereddrug 2760 2772	fluorouracil
T87	indication 2817 2822	SCCHN
T89	adversereaction 3005 3017	anaphylaxis)
T91	routeofadministration 3030 3048	intravenously (IV)
T93	frequency 3059 3073	every 3 weeks.
T95	tradename 3158 3166	TAXOTERE
T97	indication 3193 3227	BC locally advanced or metastatic:
T99	dose 3228 3236	60 mg/m2
T101	dose 3240 3249	100 mg/m2
T103	indication 3291 3303	BC adjuvant:
T105	dose 3304 3312	75 mg/m2
T107	co-administereddrug 3339 3350	doxorubicin
T109	dose 3351 3359	50 mg/m2
T111	co-administereddrug 3364 3380	cyclophosphamide
T113	dose 3381 3390	500 mg/m2
T115	frequency 3391 3417	every 3 weeks for 6 cycles
T117	indication 3446 3452	NSCLC:
T119	dose 3485 3493	75 mg/m2
T121	indication 3535 3541	NSCLC:
T123	dose 3562 3570	75 mg/m2
T125	co-administereddrug 3583 3592	cisplatin
T127	dose 3593 3601	75 mg/m2
T129	indication 3630 3635	HRPC:
T131	dose 3636 3644	75 mg/m2
T133	dose 3650 3654	5 mg
T135	co-administereddrug 3655 3665	prednisone
T137	frequency 3666 3677	twice a day
T139	dose 3723 3731	75 mg/m2
T141	co-administereddrug 3744 3753	cisplatin
T143	dose 3754 3762	75 mg/m2
T145	co-administereddrug 3795 3807	fluorouracil
T147	dose 3808 3817	750 mg/m2
T149	frequency 3818 3825	per day
T151	routeofadministration 3837 3839	IV
T153	co-administereddrug 3871 3880	cisplatin
T155	indication 3907 3913	SCCHN:
T157	dose 3914 3922	75 mg/m2
T159	dose 3945 3953	75 mg/m2
T161	routeofadministration 3954 3956	IV
T163	co-administereddrug 3979 3991	fluorouracil
T165	dose 3992 4001	750 mg/m2
T167	routeofadministration 4021 4023	IV
T169	co-administereddrug 4055 4064	cisplatin
T171	indication 4116 4122	SCCHN:
T173	dose 4123 4131	75 mg/m2
T175	co-administereddrug 4144 4153	cisplatin
T177	dose 4154 4163	100 mg/m2
T179	routeofadministration 4164 4166	IV
T181	co-administereddrug 4188 4200	fluorouracil
T183	dose 4201 4211	1000 mg/m2
T185	frequency 4212 4219	per day
T187	routeofadministration 4231 4233	IV
T189	routeofadministration 4333 4337	oral
T191	co-administereddrug 4338 4353	corticosteroids
T193	tradename 4509 4518	TAXOTERE:
T195	activeingredient 4686 4695	docetaxel
T197	inactiveingredient 4699 4713	polysorbate 80
T199	adversereaction 4876 4899	Acute myeloid leukemia:
T201	tradename 4925 4933	TAXOTERE
T203	adversereaction 4989 5003	myelodysplasia
T205	adversereaction 5007 5023	myeloid leukemia
T207	adversereaction 5041 5061	Cutaneous reactions:
T209	adversereaction 5082 5109	erythema of the extremities
T211	adversereaction 5115 5120	edema
T213	adversereaction 5133 5145	desquamation
T215	adversereaction 5157 5177	Severe skin toxicity
T217	adversereaction 5223 5244	Neurologic reactions:
T219	adversereaction 5266 5277	paresthesia
T221	adversereaction 5279 5290	dysesthesia
T223	adversereaction 5296 5300	pain
T225	adversereaction 5312 5340	Severe neurosensory symptoms
T227	adversereaction 5416 5458	Eye disorders: Cystoid macular edema (CME)
T229	adversereaction 5534 5543	Asthenia:
T231	adversereaction 5551 5559	asthenia
T233	tradename 5681 5689	TAXOTERE
T235	tradename 6042 6050	TAXOTERE
T237	tradename 6201 6209	TAXOTERE
T239	adversereaction 6226 6236	infections
T241	adversereaction 6238 6249	neutropenia
T243	adversereaction 6251 6257	anemia
T245	adversereaction 6259 6278	febrile neutropenia
T247	adversereaction 6280 6296	hypersensitivity
T249	adversereaction 6298 6314	thrombocytopenia
T251	adversereaction 6316 6326	neuropathy
T253	adversereaction 6328 6337	dysgeusia
T255	adversereaction 6339 6346	dyspnea
T257	adversereaction 6348 6360	constipation
T259	adversereaction 6362 6370	anorexia
T261	adversereaction 6372 6386	nail disorders
T263	adversereaction 6388 6403	fluid retention
T265	adversereaction 6405 6413	asthenia
T267	adversereaction 6415 6419	pain
T269	adversereaction 6421 6427	nausea
T271	adversereaction 6429 6437	diarrhea
T273	adversereaction 6439 6447	vomiting
T275	adversereaction 6449 6458	mucositis
T277	adversereaction 6460 6468	alopecia
T279	adversereaction 6470 6484	skin reactions
T281	adversereaction 6486 6493	myalgia
T283	company 6567 6590	sanofi-aventis U.S. LLC
T285	activeingredient 6828 6837	docetaxel
T287	adversereaction 7036 7048	TOXIC DEATHS
T289	adversereaction 7050 7064	HEPATOTOXICITY
T291	adversereaction 7066 7077	NEUTROPENIA
T293	adversereaction 7121 7147	HYPERSENSITIVITY REACTIONS
T295	adversereaction 7153 7168	FLUID RETENTION
T297	indication 7302 7315	Breast Cancer
T299	indication 7373 7399	Non-Small Cell Lung Cancer
T301	indication 7445 7460	Prostate Cancer
T303	indication 7512 7534	Gastric Adenocarcinoma
T305	indication 7581 7601	Head and Neck Cancer
T307	indication 7725 7738	Breast Cancer
T309	indication 7788 7814	Non-Small Cell Lung Cancer
T311	indication 7866 7881	Prostate Cancer
T313	indication 7923 7945	Gastric Adenocarcinoma
T315	indication 8008 8028	Head and Neck Cancer
T317	indication 8512 8525	Breast Cancer
T319	indication 8615 8628	Breast Cancer
T321	indication 8687 8713	Non-Small Cell Lung Cancer
T323	indication 8787 8821	Hormone Refractory Prostate Cancer
T325	adversereaction 8837 8849	Toxic Deaths
T327	indication 8866 8888	Gastric Adenocarcinoma
T329	indication 8939 8959	Head and Neck Cancer
T331	adversereaction 8975 8994	Hematologic Effects
T333	adversereaction 9046 9072	Hypersensitivity Reactions
T335	adversereaction 9088 9103	Fluid Retention
T337	adversereaction 9125 9127	16
T339	adversereaction 9206 9228	Acute Myeloid Leukemia
T341	adversereaction 9244 9262	Cutaneous Reaction
T343	adversereaction 9273 9275	16
T345	adversereaction 9290 9310	Neurologic Reactions
T347	adversereaction 9321 9323	16
T349	adversereaction 9363 9376	Eye Disorders
T351	adversereaction 9398 9400	17
T353	adversereaction 9448 9456	Asthenia
T355	adversereaction 9691 9703	TOXIC DEATHS
T357	adversereaction 9705 9719	HEPATOTOXICITY
T359	adversereaction 9721 9732	NEUTROPENIA
T361	adversereaction 9733 9759	HYPERSENSITIVITY REACTIONS
T363	adversereaction 9765 9780	FLUID RETENTION
T365	adversereaction 9838 9847	mortality
T367	tradename 9864 9872	TAXOTERE
T369	indication 9993 10022	non-small cell lung carcinoma
T371	tradename 10101 10109	TAXOTERE
T373	dose 10141 10150	100 mg/m2
T375	tradename 10200 10208	TAXOTERE
T377	adversereaction 10557 10576	grade 4 neutropenia
T379	adversereaction 10578 10597	febrile neutropenia
T381	adversereaction 10599 10609	infections
T383	adversereaction 10611 10634	severe thrombocytopenia
T385	adversereaction 10636 10653	severe stomatitis
T387	adversereaction 10655 10675	severe skin toxicity
T389	adversereaction 10681 10693	toxic death.
T391	adversereaction 10795 10814	febrile neutropenia
T393	tradename 10976 10984	TAXOTERE
T395	tradename 11042 11050	TAXOTERE
T397	adversereaction 11175 11186	neutropenia
T399	tradename 11306 11314	TAXOTERE
T401	adversereaction 11371 11397	hypersensitivity reactions
T403	adversereaction 11427 11440	rash/erythema
T405	adversereaction 11442 11453	hypotension
T407	adversereaction 11461 11473	bronchospasm
T409	adversereaction 11496 11507	anaphylaxis
T411	co-administereddrug 11561 11574	dexamethasone
T413	adversereaction 11601 11627	Hypersensitivity reactions
T415	tradename 11669 11677	TAXOTERE
T417	tradename 11778 11786	TAXOTERE
T419	adversereaction 11846 11872	hypersensitivity reactions
T421	tradename 11876 11884	TAXOTERE
T423	inactiveingredient 11919 11933	polysorbate 80
T425	adversereaction 11981 11996	fluid retention
T427	co-administereddrug 12056 12069	dexamethasone
T429	adversereaction 12182 12198	peripheral edema
T431	adversereaction 12212 12217	edema
T433	adversereaction 12219 12235	pleural effusion
T435	adversereaction 12263 12270	dyspnea
T437	adversereaction 12280 12297	cardiac tamponade
T439	adversereaction 12302 12333	pronounced abdominal distention
T441	adversereaction 12342 12350	ascites)
T443	indication 12451 12464	Breast Cancer
T445	tradename 12476 12484	TAXOTERE
T447	indication 12564 12577	breast cancer
T449	tradename 12626 12634	TAXOTERE
T451	co-administereddrug 12655 12666	doxorubicin
T453	co-administereddrug 12671 12687	cyclophosphamide
T455	indication 12768 12782	breast cancer.
T457	indication 12798 12824	Non-Small Cell Lung Cancer
T459	tradename 12836 12844	TAXOTERE
T461	indication 12942 12968	non-small cell lung cancer
T463	tradename 13032 13040	TAXOTERE
T465	co-administereddrug 13061 13070	cisplatin
T467	indication 13164 13190	non-small cell lung cancer
T469	indication 13272 13287	Prostate Cancer
T471	tradename 13299 13307	TAXOTERE
T473	co-administereddrug 13328 13338	prednisone
T475	indication 13429 13456	metastatic prostate cancer.
T477	indication 13472 13494	Gastric Adenocarcinoma
T479	tradename 13506 13514	TAXOTERE
T481	co-administereddrug 13535 13544	cisplatin
T483	co-administereddrug 13549 13561	fluorouracil
T485	indication 13619 13641	gastric adenocarcinoma
T487	indication 13653 13700	adenocarcinoma of the gastroesophageal junction
T489	indication 13781 13801	Head and Neck Cancer
T491	tradename 13813 13821	TAXOTERE
T493	co-administereddrug 13842 13851	cisplatin
T495	co-administereddrug 13856 13868	fluorouracil
T497	indication 13944 13997	squamous cell carcinoma of the head and neck (SCCHN).
T499	adversereaction 14257 14269	anaphylaxis)
T501	indication 14297 14310	Breast Cancer
T503	indication 14357 14370	breast cancer
T505	tradename 14432 14440	TAXOTERE
T507	dose 14444 14452	60 mg/m2
T509	dose 14456 14465	100 mg/m2
T511	routeofadministration 14479 14492	intravenously
T513	frequency 14505 14519	every 3 weeks.
T515	indication 14570 14597	node-positive breast cancer
T517	tradename 14615 14623	TAXOTERE
T519	dose 14632 14640	75 mg/m2
T521	co-administereddrug 14667 14678	doxorubicin
T523	dose 14679 14687	50 mg/m2
T525	co-administereddrug 14692 14708	cyclophosphamide
T527	dose 14709 14718	500 mg/m2
T529	frequency 14719 14747	every 3 weeks for 6 courses.
T531	indication 14904 14930	Non-Small Cell Lung Cancer
T533	tradename 15008 15016	TAXOTERE
T535	dose 15075 15083	75 mg/m2
T537	routeofadministration 15097 15110	intravenously
T539	frequency 15123 15137	every 3 weeks.
T541	dose 15159 15168	100 mg/m2
T543	tradename 15508 15516	TAXOTERE
T545	co-administereddrug 15551 15561	cisplatin.
T547	tradename 15597 15605	TAXOTERE
T549	dose 15609 15617	75 mg/m2
T551	routeofadministration 15631 15644	intravenously
T553	co-administereddrug 15681 15690	cisplatin
T555	dose 15691 15699	75 mg/m2
T557	frequency 15719 15732	every 3 weeks
T559	indication 15798 15813	Prostate Cancer
T561	indication 15829 15874	hormone-refractory metastatic prostate cancer
T563	tradename 15900 15908	TAXOTERE
T565	dose 15912 15920	75 mg/m2
T567	frequency 15921 15934	every 3 weeks
T569	routeofadministration 15947 15958	intravenous
T571	co-administereddrug 15980 15990	Prednisone
T573	dose 15991 15995	5 mg
T575	routeofadministration 15996 16002	orally
T577	frequency 16003 16014	twice daily
T579	indication 16109 16131	Gastric Adenocarcinoma
T581	indication 16147 16169	gastric adenocarcinoma
T583	tradename 16195 16203	TAXOTERE
T585	dose 16207 16215	75 mg/m2
T587	routeofadministration 16228 16239	intravenous
T589	co-administereddrug 16262 16271	cisplatin
T591	dose 16272 16280	75 mg/m2
T593	routeofadministration 16299 16310	intravenous
T595	co-administereddrug 16354 16366	fluorouracil
T597	dose 16367 16376	750 mg/m2
T599	frequency 16377 16384	per day
T601	routeofadministration 16415 16426	intravenous
T603	co-administereddrug 16475 16484	cisplatin
T605	frequency 16529 16547	every three weeks.
T607	co-administereddrug 16589 16600	antiemetics
T609	co-administereddrug 16631 16640	cisplatin
T611	indication 16721 16741	Head and Neck Cancer
T613	co-administereddrug 16794 16805	antiemetics
T615	co-administereddrug 16853 16862	cisplatin
T617	tradename 16994 17002	TAXOTERE
T619	indication 17214 17219	SCCHN
T621	tradename 17245 17253	TAXOTERE
T623	dose 17257 17265	75 mg/m2
T625	routeofadministration 17278 17289	intravenous
T627	co-administereddrug 17311 17320	cisplatin
T629	dose 17321 17329	75 mg/m2
T631	routeofadministration 17330 17343	intravenously
T633	co-administereddrug 17381 17393	fluorouracil
T635	routeofadministration 17410 17421	intravenous
T637	dose 17434 17443	750 mg/m2
T639	frequency 17444 17466	per day for five days.
T641	frequency 17507 17534	every 3 weeks for 4 cycles.
T643	indication 17852 17857	SCCHN
T645	tradename 17883 17891	TAXOTERE
T647	dose 17895 17903	75 mg/m2
T649	routeofadministration 17916 17927	intravenous
T651	co-administereddrug 17959 17968	cisplatin
T653	dose 17969 17978	100 mg/m2
T655	co-administereddrug 18039 18051	fluorouracil
T657	dose 18052 18062	1000 mg/m2
T659	frequency 18062 18066	/day
T661	frequency 18143 18170	every 3 weeks for 3 cycles.
T663	routeofadministration 18387 18391	oral
T665	co-administereddrug 18392 18407	corticosteroids
T667	indication 18423 18439	prostate cancer)
T669	co-administereddrug 18448 18461	dexamethasone
T671	dose 18462 18467	16 mg
T673	frequency 18468 18475	per day
T675	dose 18483 18487	8 mg
T677	frequency 18488 18500	twice daily)
T679	tradename 18536 18544	TAXOTERE
T681	adversereaction 18609 18624	fluid retention
T683	adversereaction 18652 18678	hypersensitivity reactions
T685	indication 18758 18803	hormone-refractory metastatic prostate cancer
T687	co-administereddrug 18833 18843	prednisone
T689	routeofadministration 18886 18890	oral
T691	co-administereddrug 18891 18904	dexamethasone
T693	dose 18905 18909	8 mg
T695	tradename 18954 18962	TAXOTERE
T697	indication 19083 19096	Breast Cancer
T699	dose 19133 19142	100 mg/m2
T701	adversereaction 19169 19188	febrile neutropenia
T703	adversereaction 19266 19285	cutaneous reactions
T705	tradename 19293 19301	TAXOTERE
T707	dose 19347 19356	100 mg/m2
T709	dose 19360 19369	75 mg/m2.
T711	dose 19480 19488	75 mg/m2
T713	dose 19492 19500	55 mg/m2
T715	dose 19590 19598	60 mg/m2
T717	adversereaction 19719 19738	cutaneous reactions
T719	adversereaction 19750 19771	peripheral neuropathy
T721	tradename 19779 19787	TAXOTERE
T723	adversereaction 19873 19894	peripheral neuropathy
T725	tradename 19907 19915	TAXOTERE
T727	tradename 19996 20004	TAXOTERE
T729	indication 20034 20047	Breast Cancer
T731	tradename 20048 20056	TAXOTERE
T733	co-administereddrug 20077 20088	doxorubicin
T735	co-administereddrug 20093 20109	cyclophosphamide
T737	adversereaction 20226 20245	febrile neutropenia
T739	tradename 20393 20401	TAXOTERE
T741	dose 20418 20426	60 mg/m.
T743	adversereaction 20475 20485	stomatitis
T745	tradename 20504 20512	TAXOTERE
T747	dose 20531 20539	60 mg/m.
T749	adversereaction 20596 20615	cutaneous reactions
T751	tradename 20670 20678	TAXOTERE
T753	tradename 20715 20723	TAXOTERE
T755	dose 20737 20744	75 mg/m
T757	dose 20748 20756	60 mg/m.
T759	dose 20815 20822	60 mg/m
T761	indication 20880 20906	Non-Small Cell Lung Cancer
T763	tradename 20924 20932	TAXOTERE
T765	indication 20937 20942	NSCLC
T767	dose 21040 21048	75 mg/m2
T769	adversereaction 21075 21094	febrile neutropenia
T771	adversereaction 21171 21190	cutaneous reactions
T773	tradename 21247 21255	TAXOTERE
T775	dose 21350 21359	55 mg/m2.
T777	adversereaction 21399 21420	peripheral neuropathy
T779	tradename 21433 21441	TAXOTERE
T781	tradename 21522 21530	TAXOTERE
T783	tradename 21600 21608	TAXOTERE
T785	dose 21609 21617	75 mg/m2
T787	co-administereddrug 21638 21647	cisplatin
T789	adversereaction 21773 21792	febrile neutropenia
T791	tradename 21855 21863	TAXOTERE
T793	dose 21913 21921	65 mg/m2
T795	dose 21995 22003	50 mg/m2
T797	indication 22109 22124	Prostate Cancer
T799	tradename 22150 22158	TAXOTERE
T801	indication 22163 22208	hormone-refractory metastatic prostate cancer
T803	tradename 22209 22217	TAXOTERE
T805	adversereaction 22341 22360	febrile neutropenia
T807	adversereaction 22437 22456	cutaneous reactions
T809	tradename 22511 22519	TAXOTERE
T811	tradename 22554 22562	TAXOTERE
T813	dose 22576 22583	75 mg/m
T815	dose 22587 22595	60 mg/m.
T817	dose 22665 22672	60 mg/m
T819	indication 22737 22768	Gastric or Head and Neck Cancer
T821	tradename 22769 22777	TAXOTERE
T823	co-administereddrug 22798 22807	cisplatin
T825	co-administereddrug 22812 22824	fluorouracil
T827	indication 22828 22866	gastric cancer or head and neck cancer
T829	tradename 22889 22897	TAXOTERE
T831	co-administereddrug 22918 22927	cisplatin
T833	co-administereddrug 22932 22944	fluorouracil
T835	co-administereddrug 22958 22969	antiemetics
T837	adversereaction 23147 23166	febrile neutropenia
T839	adversereaction 23182 23208	infection with neutropenia
T841	adversereaction 23213 23250	neutropenia lasting more than 7 days.
T843	adversereaction 23279 23298	febrile neutropenia
T845	adversereaction 23300 23321	prolonged neutropenia
T847	adversereaction 23325 23346	neutropenic infection
T849	tradename 23377 23385	TAXOTERE
T851	dose 23414 23422	75 mg/m2
T853	dose 23426 23434	60 mg/m2
T855	adversereaction 23474 23497	complicated neutropenia
T857	tradename 23508 23516	TAXOTERE
T859	dose 23545 23553	60 mg/m2
T861	dose 23557 23565	45 mg/m2
T863	adversereaction 23590 23614	grade 4 thrombocytopenia
T865	tradename 23619 23627	TAXOTERE
T867	dose 23656 23664	75 mg/m2
T869	dose 23668 23677	60 mg/m2.
T871	tradename 23748 23756	TAXOTERE
T873	tradename 24065 24073	TAXOTERE
T875	co-administereddrug 24094 24103	cisplatin
T877	co-administereddrug 24108 24120	fluorouracil
T879	tradename 24235 24243	TAXOTERE
T881	co-administereddrug 24264 24273	Cisplatin
T883	co-administereddrug 24278 24290	Fluorouracil
T885	adversereaction 24340 24356	Diarrhea grade 3
T887	co-administereddrug 24379 24391	fluorouracil
T889	tradename 24444 24452	TAXOTERE
T891	adversereaction 24466 24482	Diarrhea grade 4
T893	tradename 24505 24513	TAXOTERE
T895	co-administereddrug 24518 24530	fluorouracil
T897	adversereaction 24595 24623	Stomatitis/mucositis grade 3
T899	co-administereddrug 24657 24669	fluorouracil
T901	co-administereddrug 24704 24716	fluorouracil
T903	tradename 24771 24779	TAXOTERE
T905	adversereaction 24804 24832	Stomatitis/mucositis grade 4
T907	co-administereddrug 24864 24876	fluorouracil
T909	tradename 24932 24940	TAXOTERE
T911	adversereaction 24965 24983	Liver dysfunction:
T913	tradename 25137 25145	TAXOTERE
T915	tradename 25236 25244	TAXOTERE
T917	co-administereddrug 25302 25311	cisplatin
T919	co-administereddrug 25316 25328	fluorouracil
T921	adversereaction 25336 25350	gastric cancer
T923	co-administereddrug 25377 25386	Cisplatin
T925	adversereaction 25417 25439	Peripheral neuropathy:
T927	co-administereddrug 25787 25796	cisplatin
T929	adversereaction 25864 25876	Ototoxicity:
T931	adversereaction 25955 25970	Nephrotoxicity:
T933	adversereaction 25989 26013	rise in serum creatinine
T935	co-administereddrug 26233 26242	cisplatin
T937	co-administereddrug 26468 26477	Cisplatin
T939	co-administereddrug 26543 26552	cisplatin
T941	co-administereddrug 26700 26709	cisplatin
T943	co-administereddrug 26809 26818	cisplatin
T945	co-administereddrug 26905 26914	cisplatin
T947	co-administereddrug 27018 27027	cisplatin
T949	co-administereddrug 27134 27143	cisplatin
T951	co-administereddrug 27233 27242	cisplatin
T953	co-administereddrug 27336 27345	cisplatin
T955	co-administereddrug 27437 27449	Fluorouracil
T957	adversereaction 27494 27502	diarrhea
T959	adversereaction 27507 27517	stomatitis
T961	adversereaction 27578 27601	plantar-palmar toxicity
T963	co-administereddrug 27603 27615	fluorouracil
T965	co-administereddrug 27665 27677	fluorouracil
T967	adversereaction 27772 27780	alopecia
T969	adversereaction 27785 27791	anemia
T971	co-administereddrug 28003 28015	fluorouracil
T973	activeingredient 28580 28589	docetaxel
T975	tradename 28797 28805	TAXOTERE
T977	tradename 28941 28949	TAXOTERE
T979	tradename 29096 29104	TAXOTERE
T981	tradename 29292 29300	TAXOTERE
T983	tradename 29500 29508	TAXOTERE
T985	tradename 29787 29795	TAXOTERE
T987	tradename 30009 30017	TAXOTERE
T989	tradename 30041 30049	TAXOTERE
T991	tradename 30420 30428	TAXOTERE
T993	tradename 30452 30460	TAXOTERE
T995	tradename 30632 30640	TAXOTERE
T997	tradename 30786 30794	TAXOTERE
T999	tradename 30947 30955	TAXOTERE
T1001	tradename 31152 31160	TAXOTERE
T1003	activeingredient 31190 31200	docetaxel/
T1005	tradename 31481 31489	TAXOTERE
T1007	tradename 31585 31593	TAXOTERE
T1009	tradename 31748 31756	TAXOTERE
T1011	tradename 31923 31931	TAXOTERE
T1013	routeofadministration 31945 31956	intravenous
T1015	tradename 32062 32070	TAXOTERE
T1017	tradename 32262 32270	TAXOTERE
T1019	routeofadministration 32316 32329	intravenously
T1021	tradename 32466 32474	TAXOTERE
T1023	tradename 32581 32589	TAXOTERE
T1025	routeofadministration 32736 32747	intravenous
T1027	tradename 33046 33054	TAXOTERE
T1029	tradename 33090 33098	TAXOTERE
T1031	tradename 33108 33116	TAXOTERE
T1033	activeingredient 33118 33128	docetaxel)
T1035	activeingredient 33169 33178	docetaxel
T1037	inactiveingredient 33208 33242	polysorbate 80/dehydrated alcohol.
T1039	tradename 33254 33262	TAXOTERE
T1041	tradename 33274 33282	TAXOTERE
T1043	activeingredient 33284 33294	docetaxel)
T1045	activeingredient 33335 33344	docetaxel
T1047	inactiveingredient 33371 33405	polysorbate 80/dehydrated alcohol.
T1049	tradename 33460 33468	TAXOTERE
T1051	activeingredient 33559 33568	docetaxel
T1053	inactiveingredient 33603 33618	polysorbate 80.
T1055	adversereaction 33659 33670	anaphylaxis
T1057	tradename 33735 33743	TAXOTERE
T1059	adversereaction 33897 33909	Toxic Deaths
T1061	indication 33921 33934	Breast Cancer
T1063	tradename 33935 33943	TAXOTERE
T1065	dose 33960 33969	100 mg/m2
T1067	adversereaction 33990 33996	deaths
T1069	indication 34070 34094	metastatic breast cancer
T1071	dose 34373 34381	60 mg/m2
T1073	adversereaction 34384 34393	mortality
T1075	adversereaction 34572 34578	deaths
T1077	adversereaction 34612 34618	Sepsis
T1079	adversereaction 34653 34660	deaths.
T1081	indication 34683 34709	Non-Small Cell Lung Cancer
T1083	tradename 34710 34718	TAXOTERE
T1085	dose 34745 34754	100 mg/m2
T1087	indication 34803 34829	non-small cell lung cancer
T1089	adversereaction 34933 34942	mortality
T1091	adversereaction 35040 35046	deaths
T1093	dose 35085 35093	75 mg/m2
T1095	adversereaction 35185 35194	mortality
T1097	dose 35202 35210	75 mg/m2
T1099	tradename 35498 35506	TAXOTERE
T1101	tradename 35715 35724	TAXOTERE.
T1103	tradename 35796 35804	TAXOTERE
T1105	tradename 35961 35969	TAXOTERE
T1107	adversereaction 36020 36038	severe neutropenia
T1109	adversereaction 36083 36102	febrile neutropenia
T1111	adversereaction 36109 36126	grade 4 infection
T1113	tradename 36132 36140	TAXOTERE
T1115	adversereaction 36208 36219	Neutropenia
T1117	dose 36286 36294	60 mg/m2
T1119	dose 36298 36307	100 mg/m2
T1121	tradename 36311 36319	TAXOTERE
T1123	adversereaction 36324 36343	grade 4 neutropenia
T1125	dose 36396 36405	100 mg/m2
T1127	dose 36432 36441	60 mg/m2.
T1129	tradename 36544 36552	TAXOTERE
T1131	adversereaction 36652 36671	Febrile neutropenia
T1133	dose 36712 36721	100 mg/m2
T1135	dose 36762 36771	60 mg/m2.
T1137	adversereaction 36783 36804	Hematologic responses
T1139	adversereaction 36806 36838	febrile reactions and infections
T1141	adversereaction 36853 36865	septic death
T1143	indication 36988 37001	breast cancer
T1145	adversereaction 37086 37111	gastrointestinal bleeding
T1147	adversereaction 37148 37165	thrombocytopenia.
T1149	indication 37181 37195	gastric cancer
T1151	activeingredient 37218 37227	docetaxel
T1153	co-administereddrug 37248 37257	cisplatin
T1155	co-administereddrug 37262 37274	fluorouracil
T1157	adversereaction 37282 37301	febrile neutropenia
T1159	adversereaction 37309 37330	neutropenic infection
T1161	adversereaction 37509 37528	febrile neutropenia
T1163	adversereaction 37533 37554	neutropenic infection
T1165	adversereaction 37643 37669	Hypersensitivity Reactions
T1167	adversereaction 37721 37747	hypersensitivity reactions
T1169	adversereaction 37817 37843	hypersensitivity reactions
T1171	adversereaction 37873 37886	rash/erythema
T1173	adversereaction 37888 37899	hypotension
T1175	adversereaction 37907 37919	bronchospasm
T1177	adversereaction 37942 37953	anaphylaxis
T1179	co-administereddrug 38014 38030	corticosteroids.
T1181	adversereaction 38049 38075	hypersensitivity reactions
T1183	tradename 38117 38125	TAXOTERE
T1185	tradename 38263 38272	TAXOTERE.
T1187	adversereaction 38295 38321	Hypersensitivity reactions
T1189	tradename 38379 38387	TAXOTERE
T1191	adversereaction 38436 38444	flushing
T1193	adversereaction 38448 38472	localized skin reactions
T1195	routeofadministration 38576 38580	oral
T1197	co-administereddrug 38581 38595	corticosteroid
T1199	tradename 38639 38647	TAXOTERE
T1201	adversereaction 38713 38728	Fluid Retention
T1203	adversereaction 38747 38762	fluid retention
T1205	tradename 38791 38799	TAXOTERE
T1207	routeofadministration 38857 38861	oral
T1209	co-administereddrug 38862 38877	corticosteroids
T1211	tradename 38892 38900	TAXOTERE
T1213	adversereaction 38956 38971	fluid retention
T1215	adversereaction 39206 39222	peripheral edema
T1217	indication 39345 39358	breast cancer
T1219	co-administereddrug 39392 39407	corticosteroids
T1221	adversereaction 39418 39433	fluid retention
T1223	adversereaction 39463 39478	fluid retention
T1225	adversereaction 39546 39561	fluid retention
T1227	adversereaction 39657 39673	fluid retention:
T1229	adversereaction 39710 39725	fluid retention
T1231	adversereaction 39764 39780	fluid retention.
T1233	adversereaction 39855 39870	fluid retention
T1235	dose 39875 39886	1021 mg/m2.
T1237	adversereaction 39887 39902	Fluid retention
T1239	tradename 40004 40012	TAXOTERE
T1241	adversereaction 40083 40099	peripheral edema
T1243	adversereaction 40207 40229	Acute Myeloid Leukemia
T1245	adversereaction 40259 40287	acute myeloid leukemia (AML)
T1247	adversereaction 40291 40305	myelodysplasia
T1249	indication 40415 40429	breast cancer.
T1251	indication 40457 40470	breast cancer
T1253	tradename 40533 40541	TAXOTERE
T1255	adversereaction 40743 40757	myelodysplasia
T1257	adversereaction 40761 40777	myeloid leukemia
T1259	adversereaction 40838 40857	Cutaneous Reactions
T1261	adversereaction 40869 40887	Localized erythema
T1263	adversereaction 40912 40917	edema
T1265	adversereaction 40930 40942	desquamation
T1267	indication 41162 41186	metastatic breast cancer
T1269	indication 41217 41230	breast cancer
T1271	co-administereddrug 41264 41279	corticosteroids
T1273	tradename 41362 41370	TAXOTERE
T1275	adversereaction 41419 41439	Neurologic Reactions
T1277	adversereaction 41451 41479	Severe neurosensory symptoms
T1279	adversereaction 41486 41497	paresthesia
T1281	adversereaction 41499 41510	dysesthesia
T1283	adversereaction 41512 41517	pain)
T1285	indication 41552 41576	metastatic breast cancer
T1287	adversereaction 41830 41843	neurotoxicity
T1289	adversereaction 42068 42095	peripheral motor neuropathy
T1291	adversereaction 42221 42248	Cystoid macular edema (CME)
T1293	tradename 42292 42301	TAXOTERE.
T1295	adversereaction 42427 42430	CME
T1297	tradename 42445 42453	TAXOTERE
T1299	adversereaction 42624 42632	Asthenia
T1301	adversereaction 42651 42659	asthenia
T1303	indication 42700 42724	metastatic breast cancer
T1305	activeingredient 43095 43104	docetaxel
T1307	tradename 43177 43185	TAXOTERE
T1309	tradename 43402 43410	TAXOTERE
T1311	tradename 43526 43534	TAXOTERE
T1313	dose 43548 43557	100 mg/m2
T1315	inactiveingredient 43579 43587	ethanol.
T1317	inactiveingredient 43656 43663	ethanol
T1319	activeingredient 43705 43714	docetaxel
T1321	tradename 43819 43827	TAXOTERE
T1323	activeingredient 43899 43908	Docetaxel
T1325	tradename 44293 44302	TAXOTERE.
T1327	tradename 44317 44325	TAXOTERE
T1329	tradename 44591 44599	TAXOTERE
T1331	tradename 44735 44743	TAXOTERE
T1333	adversereaction 44760 44772	Toxic Deaths
T1335	adversereaction 44835 44849	Hepatotoxicity
T1337	adversereaction 44913 44924	Neutropenia
T1339	adversereaction 44989 45005	Hypersensitivity
T1341	adversereaction 45069 45084	Fluid Retention
T1343	tradename 45204 45212	TAXOTERE
T1345	adversereaction 45241 45252	neutropenia
T1347	adversereaction 45254 45260	anemia
T1349	adversereaction 45262 45281	febrile neutropenia
T1351	adversereaction 45283 45299	hypersensitivity
T1353	adversereaction 45301 45317	thrombocytopenia
T1355	adversereaction 45319 45329	neuropathy
T1357	adversereaction 45331 45340	dysgeusia
T1359	adversereaction 45342 45349	dyspnea
T1361	adversereaction 45351 45363	constipation
T1363	adversereaction 45365 45373	anorexia
T1365	adversereaction 45375 45389	nail disorders
T1367	adversereaction 45391 45406	fluid retention
T1369	adversereaction 45408 45416	asthenia
T1371	adversereaction 45418 45422	pain
T1373	adversereaction 45424 45430	nausea
T1375	adversereaction 45432 45440	diarrhea
T1377	adversereaction 45442 45450	vomiting
T1379	adversereaction 45452 45461	mucositis
T1381	adversereaction 45463 45471	alopecia
T1383	adversereaction 45473 45487	skin reactions
T1385	adversereaction 45493 45501	myalgia.
T1387	indication 46254 46267	Breast Cancer
T1389	tradename 46285 46293	TAXOTERE
T1391	indication 46298 46342	locally advanced or metastatic breast cancer
T1393	tradename 46379 46387	TAXOTERE
T1395	dose 46388 46398	100 mg/m2:
T1397	tradename 46518 46526	TAXOTERE
T1399	dose 46543 46552	100 mg/m2
T1401	frequency 46574 46588	every 3 weeks:
T1403	indication 46713 46757	locally advanced or metastatic breast cancer
T1405	tradename 47082 47091	TAXOTERE.
T1407	tradename 47246 47254	TAXOTERE
T1409	indication 47276 47289	breast cancer
T1411	tradename 47416 47424	TAXOTERE
T1413	dose 47428 47437	100 mg/m2
T1415	indication 47532 47545	Breast Cancer
T1417	adversereaction 47634 47645	Neutropenia
T1419	indication 47817 47830	Breast Cancer
T1421	adversereaction 47931 47941	Leukopenia
T1423	adversereaction 48020 48036	Thrombocytopenia
T1425	adversereaction 48090 48096	Anemia
T1427	adversereaction 48165 48185	Febrile Neutropenia*
T1429	adversereaction 48197 48226	Septic Death Non-Septic Death
T1431	adversereaction 48283 48293	Infections
T1433	adversereaction 48365 48370	Fever
T1435	adversereaction 48432 48458	Hypersensitivity Reactions
T1437	adversereaction 48601 48616	Fluid Retention
T1439	indication 48956 48969	Breast Cancer
T1441	adversereaction 49107 49119	Nail Changes
T1443	adversereaction 49207 49231	Nausea Vomiting Diarrhea
T1445	adversereaction 49327 49337	Stomatitis
T1447	adversereaction 49409 49417	Alopecia
T1449	adversereaction 49427 49435	Asthenia
T1451	adversereaction 49509 49516	Myalgia
T1453	adversereaction 49587 49597	Arthralgia
T1455	adversereaction 49604 49627	Infusion Site Reactions
T1457	adversereaction 49942 49962	Febrile Neutropenia:
T1459	adversereaction 49980 49985	fever
T1461	routeofadministration 50000 50011	intravenous
T1463	adversereaction 50091 50120	Reversible marrow suppression
T1465	tradename 50161 50169	TAXOTERE
T1467	adversereaction 50274 50292	severe neutropenia
T1469	adversereaction 50499 50518	Febrile neutropenia
T1471	routeofadministration 50563 50574	intravenous
T1473	indication 50684 50708	metastatic breast cancer
T1475	indication 50728 50741	breast cancer
T1477	co-administereddrug 50775 50791	corticosteroids.
T1479	indication 50903 50927	metastatic breast cancer
T1481	indication 50947 50960	breast cancer
T1483	co-administereddrug 50994 51010	corticosteroids.
T1485	adversereaction 51033 51049	Thrombocytopenia
T1487	adversereaction 51090 51123	fatal gastrointestinal hemorrhage
T1489	adversereaction 51154 51214	Hypersensitivity Reactions Severe hypersensitivity reactions
T1491	adversereaction 51322 51330	flushing
T1493	adversereaction 51332 51336	rash
T1495	adversereaction 51353 51361	pruritus
T1497	adversereaction 51363 51378	chest tightness
T1499	adversereaction 51380 51389	back pain
T1501	adversereaction 51391 51398	dyspnea
T1503	adversereaction 51400 51410	drug fever
T1505	adversereaction 51415 51421	chills
T1507	adversereaction 51547 51579	Fluid Retention. Fluid retention
T1509	tradename 51606 51614	TAXOTERE
T1511	adversereaction 51712 51752	Cutaneous Reactions Severe skin toxicity
T1513	adversereaction 51888 51892	rash
T1515	adversereaction 52020 52028	pruritus
T1517	tradename 52110 52118	TAXOTERE
T1519	adversereaction 52207 52221	nail disorders
T1521	adversereaction 52244 52270	hypo- or hyperpigmentation
T1523	adversereaction 52292 52303	onycholysis
T1525	adversereaction 52348 52353	pain.
T1527	adversereaction 52365 52406	Neurologic Reactions Neurologic reactions
T1529	adversereaction 52530 52536	Nausea
T1531	adversereaction 52538 52546	vomiting
T1533	adversereaction 52552 52560	diarrhea
T1535	indication 52699 52723	metastatic breast cancer
T1537	indication 52805 52818	breast cancer
T1539	adversereaction 52898 52908	stomatitis
T1541	indication 52982 53006	metastatic breast cancer
T1543	indication 53030 53043	breast cancer
T1545	co-administereddrug 53077 53093	corticosteroids.
T1547	adversereaction 53130 53141	Hypotension
T1549	adversereaction 53263 53276	heart failure
T1551	adversereaction 53278 53295	sinus tachycardia
T1553	adversereaction 53297 53311	atrial flutter
T1555	adversereaction 53313 53324	dysrhythmia
T1557	adversereaction 53343 53358	pulmonary edema
T1559	adversereaction 53364 53376	hypertension
T1561	indication 53427 53451	metastatic breast cancer
T1563	tradename 53471 53479	TAXOTERE
T1565	dose 53480 53489	100 mg/m2
T1567	adversereaction 53717 53764	Infusion Site Reactions Infusion site reactions
T1569	adversereaction 53802 53819	hyperpigmentation
T1571	adversereaction 53821 53833	inflammation
T1573	adversereaction 53835 53865	redness or dryness of the skin
T1575	adversereaction 53878 53891	extravasation
T1577	adversereaction 53896 53917	swelling of the vein.
T1579	tradename 54248 54256	TAXOTERE
T1581	tradename 54898 54906	TAXOTERE
T1583	dose 54910 54919	100 mg/m2
T1585	indication 54964 54988	metastatic breast cancer
T1587	tradename 55234 55242	TAXOTERE
T1589	dose 55246 55254	60 mg/m2
T1591	indication 55362 55375	Breast Cancer
T1593	tradename 55433 55441	TAXOTERE
T1595	dose 55442 55451	100 mg/m2
T1597	dose 55500 55508	60 mg/m2
T1599	tradename 55581 55589	TAXOTERE
T1601	dose 55590 55599	100 mg/m2
T1603	tradename 55611 55619	TAXOTERE
T1605	dose 55620 55628	60 mg/m2
T1607	adversereaction 55760 55771	Neutropenia
T1609	adversereaction 55898 55914	Thrombocytopenia
T1611	adversereaction 56032 56038	Anemia
T1613	tradename 56112 56120	TAXOTERE
T1615	dose 56121 56130	100 mg/m2
T1617	tradename 56142 56150	TAXOTERE
T1619	dose 56151 56159	60 mg/m2
T1621	adversereaction 56291 56301	Infection*
T1623	adversereaction 56392 56412	Febrile Neutropenia*
T1625	adversereaction 56506 56518	Septic Death
T1627	adversereaction 56525 56541	Non-Septic Death
T1629	routeofadministration 56913 56924	intravenous
T1631	adversereaction 57109 57129	Febrile Neutropenia:
T1633	dose 57134 57143	100 mg/m2
T1635	routeofadministration 57180 57191	intravenous
T1637	dose 57232 57240	60 mg/m2
T1639	indication 57334 57347	Breast Cancer
T1641	tradename 57416 57424	TAXOTERE
T1643	dose 57425 57434	100 mg/m2
T1645	dose 57505 57513	60 mg/m2
T1647	tradename 57597 57605	TAXOTERE
T1649	dose 57606 57615	100 mg/m2
T1651	tradename 57627 57635	TAXOTERE
T1653	dose 57636 57644	60 mg/m2
T1655	adversereaction 57776 57798	Acute Hypersensitivity
T1657	adversereaction 57926 57942	Fluid Retention*
T1659	tradename 58118 58126	TAXOTERE
T1661	dose 58127 58136	100 mg/m2
T1663	tradename 58148 58156	TAXOTERE
T1665	dose 58157 58165	60 mg/m2
T1667	adversereaction 58367 58374	Myalgia
T1669	adversereaction 58475 58483	Asthenia
T1671	adversereaction 58556 58564	Diarrhea
T1673	adversereaction 58634 58644	Stomatitis
T1675	adversereaction 59057 59072	Fluid Retention
T1677	adversereaction 59096 59101	edema
T1679	dose 59285 59293	60 mg/m2
T1681	tradename 59399 59407	TAXOTERE
T1683	dose 59408 59416	60 mg/m2
T1685	dose 59419 59427	75 mg/m2
T1687	dose 59432 59441	100 mg/m2
T1689	indication 59445 59467	advanced breast cancer
T1691	tradename 59550 59558	TAXOTERE
T1693	dose 59559 59567	60 mg/m2
T1695	dose 59609 59617	75 mg/m2
T1697	dose 59622 59631	100 mg/m2
T1699	dose 59744 59752	60 mg/m2
T1701	dose 59796 59812	75 and 100 mg/m2
T1703	adversereaction 59838 59844	Deaths
T1705	dose 59920 59928	60 mg/m2
T1707	dose 59979 59987	75 mg/m2
T1709	dose 59992 60001	100 mg/m2
T1711	activeingredient 60091 60100	docetaxel
T1713	adversereaction 60108 60123	fluid retention
T1715	dose 60146 60154	60 mg/m2
T1717	dose 60156 60164	75 mg/m2
T1719	dose 60170 60179	100 mg/m2
T1721	adversereaction 60195 60211	thrombocytopenia
T1723	adversereaction 60244 60255	neutropenia
T1725	adversereaction 60290 60309	febrile neutropenia
T1727	adversereaction 60342 60379	treatment-related grade 3/4 infection
T1729	adversereaction 60414 60420	anemia
T1731	tradename 60502 60510	TAXOTERE
T1733	indication 60540 60553	breast cancer
T1735	tradename 60679 60687	TAXOTERE
T1737	dose 60688 60695	75 mg/m
T1739	frequency 60696 60709	every 3 weeks
T1741	co-administereddrug 60730 60741	doxorubicin
T1743	co-administereddrug 60746 60762	cyclophosphamide
T1745	tradename 60912 60920	TAXOTERE
T1747	co-administereddrug 60941 60952	Doxorubicin
T1749	co-administereddrug 60957 60973	Cyclophosphamide
T1751	tradename 60984 60992	TAXOTERE
T1753	dose 60993 61002	75 mg/m2+
T1755	co-administereddrug 61003 61014	Doxorubicin
T1757	dose 61015 61024	50 mg/m2+
T1759	co-administereddrug 61025 61041	Cyclophosphamide
T1761	dose 61042 61045	500
T1763	dose 61057 61062	mg/m2
T1765	dose 61112 61122	500 mg/m2+
T1767	dose 61135 61144	50 mg/m2+
T1769	dose 61162 61165	500
T1771	dose 61177 61182	mg/m2
T1773	adversereaction 61275 61281	Anemia
T1775	adversereaction 61292 61303	Neutropenia
T1777	adversereaction 61316 61321	Fever
T1779	adversereaction 61356 61365	Infection
T1781	adversereaction 61376 61392	Thrombocytopenia
T1783	adversereaction 61403 61422	Febrile neutropenia
T1785	adversereaction 61436 61457	Neutropenic infection
T1787	adversereaction 61471 61497	Hypersensitivity reactions
T1789	adversereaction 61507 61517	Lymphedema
T1791	adversereaction 61526 61571	Fluid Retention* Peripheral edema Weight gain
T1793	adversereaction 61655 61673	Neuropathy sensory
T1795	adversereaction 61684 61698	Neuro-cortical
T1797	adversereaction 61707 61723	Neuropathy motor
T1799	adversereaction 61732 61748	Neuro-cerebellar
T1801	adversereaction 61757 61764	Syncope
T1803	adversereaction 61773 61781	Alopecia
T1805	adversereaction 61796 61809	Skin toxicity
T1807	adversereaction 61820 61834	Nail disorders
T1809	adversereaction 61845 61851	Nausea
T1811	adversereaction 61863 61873	Stomatitis
T1813	adversereaction 61884 61892	Vomiting
T1815	adversereaction 61903 61911	Diarrhea
T1817	adversereaction 61922 61934	Constipation
T1819	adversereaction 61945 61961	Taste perversion
T1821	tradename 61994 62002	TAXOTERE
T1823	dose 62003 62012	75 mg/m2+
T1825	co-administereddrug 62013 62024	Doxorubicin
T1827	dose 62025 62034	50 mg/m2+
T1829	co-administereddrug 62035 62051	Cyclophosphamide
T1831	dose 62052 62055	500
T1833	dose 62067 62072	mg/m2
T1835	dose 62122 62132	500 mg/m2+
T1837	dose 62145 62154	50 mg/m2+
T1839	dose 62172 62175	500
T1841	dose 62187 62192	mg/m2
T1843	adversereaction 62274 62282	Anorexia
T1845	adversereaction 62293 62307	Abdominal Pain
T1847	adversereaction 62317 62327	Amenorrhea
T1849	adversereaction 62342 62347	Cough
T1851	adversereaction 62358 62378	Cardiac dysrhythmias
T1853	adversereaction 62387 62401	Vasodilatation
T1855	adversereaction 62412 62423	Hypotension
T1857	adversereaction 62432 62441	Phlebitis
T1859	adversereaction 62450 62458	Asthenia
T1861	adversereaction 62470 62477	Myalgia
T1863	adversereaction 62488 62498	Arthralgia
T1865	adversereaction 62508 62528	Lacrimation disorder
T1867	adversereaction 62538 62552	Conjunctivitis
T1869	adversereaction 62830 62850	hematologic toxicity
T1871	adversereaction 63065 63070	fever
T1873	adversereaction 63103 63110	allergy
T1875	adversereaction 63329 63334	Fever
T1877	adversereaction 63484 63489	fever
T1879	adversereaction 63600 63609	Infection
T1881	adversereaction 63716 63725	infection
T1883	adversereaction 64028 64073	colitis/enteritis/large intestine perforation
T1885	adversereaction 64340 64352	dysrhythmias
T1887	adversereaction 64382 64393	hypotension
T1889	adversereaction 64426 64429	CHF
T1891	adversereaction 64562 64590	Acute Myeloid Leukemia (AML)
T1893	adversereaction 64609 64631	acute myeloid leukemia
T1895	adversereaction 64635 64649	myelodysplasia
T1897	indication 64771 64785	breast cancer.
T1899	adversereaction 64798 64801	AML
T1901	adversereaction 64909 64912	AML
T1903	indication 64938 64951	breast cancer
T1905	adversereaction 65020 65023	AML
T1907	adversereaction 65138 65141	AML
T1909	tradename 65320 65328	TAXOTERE
T1911	indication 65347 65383	locally advanced or metastatic NSCLC
T1913	tradename 65436 65444	TAXOTERE
T1915	dose 65445 65454	75 mg/m2:
T1917	indication 65602 65631	non-small cell lung carcinoma
T1919	tradename 66072 66080	TAXOTERE
T1921	indication 66100 66126	Non-Small Cell Lung Cancer
T1923	tradename 66230 66238	TAXOTERE
T1925	dose 66239 66247	75 mg/m2
T1927	adversereaction 66382 66393	Neutropenia
T1929	adversereaction 66470 66480	Leukopenia
T1931	adversereaction 66555 66571	Thrombocytopenia
T1933	adversereaction 66642 66648	Anemia
T1935	tradename 66767 66775	TAXOTERE
T1937	dose 66776 66784	75 mg/m2
T1939	adversereaction 66919 66939	Febrile Neutropenia*
T1941	adversereaction 66956 66965	Infection
T1943	adversereaction 67058 67067	Mortality
T1945	adversereaction 67082 67108	Hypersensitivity Reactions
T1947	adversereaction 67179 67194	Fluid Retention
T1949	adversereaction 67533 67539	Nausea
T1951	adversereaction 67554 67562	Vomiting
T1953	adversereaction 67577 67585	Diarrhea
T1955	adversereaction 67754 67762	Alopecia
T1957	adversereaction 67772 67780	Asthenia
T1959	adversereaction 67857 67867	Stomatitis
T1961	tradename 67918 67926	TAXOTERE
T1963	dose 67927 67935	75 mg/m2
T1965	adversereaction 68161 68174	Nail Disorder
T1967	adversereaction 68213 68220	Myalgia
T1969	adversereaction 68258 68268	Arthralgia
T1971	adversereaction 68306 68322	Taste Perversion
T1973	adversereaction 68553 68573	Febrile Neutropenia:
T1975	routeofadministration 68610 68621	intravenous
T1977	tradename 68794 68802	TAXOTERE
T1979	indication 68825 68866	advanced unresectable or metastatic NSCLC
T1981	indication 69023 69049	non-small cell lung cancer
T1983	indication 69322 69348	Non-Small Cell Lung Cancer
T1985	tradename 69368 69376	TAXOTERE
T1987	co-administereddrug 69397 69406	Cisplatin
T1989	tradename 69457 69465	TAXOTERE
T1991	dose 69466 69474	75 mg/m2
T1993	co-administereddrug 69477 69486	Cisplatin
T1995	dose 69487 69495	75 mg/m2
T1997	dose 69538 69546	25 mg/m2
T1999	dose 69559 69568	100 mg/m2
T2001	adversereaction 69599 69610	Neutropenia
T2003	adversereaction 69670 69689	Febrile Neutropenia
T2005	adversereaction 69694 69710	Thrombocytopenia
T2007	adversereaction 69768 69774	Anemia
T2009	adversereaction 69833 69842	Infection
T2011	adversereaction 69900 69905	Fever
T2013	adversereaction 69992 70018	Hypersensitivity Reaction*
T2015	adversereaction 70080 70096	Fluid Retention*
T2017	adversereaction 70157 70173	Pleural effusion
T2019	adversereaction 70248 70264	Peripheral edema
T2021	adversereaction 70339 70350	Weight gain
T2023	tradename 70553 70561	TAXOTERE
T2025	dose 70562 70570	75 mg/m2
T2027	co-administereddrug 70573 70582	Cisplatin
T2029	dose 70583 70591	75 mg/m2
T2031	dose 70634 70642	25 mg/m2
T2033	dose 70655 70664	100 mg/m2
T2035	adversereaction 70829 70835	Nausea
T2037	adversereaction 70895 70903	Vomiting
T2039	adversereaction 70962 70970	Diarrhea
T2041	adversereaction 71028 71037	Anorexia*
T2043	adversereaction 71124 71134	Stomatitis
T2045	adversereaction 71192 71200	Alopecia
T2047	adversereaction 71260 71269	Asthenia*
T2049	adversereaction 71358 71372	Nail Disorder*
T2051	adversereaction 71446 71454	Myalgia*
T2053	adversereaction 71616 71622	Deaths
T2055	activeingredient 71700 71710	docetaxel+
T2057	co-administereddrug 71710 71719	cisplatin
T2059	adversereaction 71792 71798	Deaths
T2061	activeingredient 71900 71910	docetaxel+
T2063	co-administereddrug 71910 71919	cisplatin
T2065	tradename 72067 72076	TAXOTERE+
T2067	co-administereddrug 72076 72087	carboplatin
T2069	tradename 72151 72159	TAXOTERE
T2071	adversereaction 72239 72255	thrombocytopenia
T2073	adversereaction 72257 72265	diarrhea
T2075	adversereaction 72267 72282	fluid retention
T2077	adversereaction 72284 72310	hypersensitivity reactions
T2079	adversereaction 72312 72325	skin toxicity
T2081	adversereaction 72327 72335	alopecia
T2083	adversereaction 72340 72352	nail changes
T2085	tradename 72360 72369	TAXOTERE+
T2087	co-administereddrug 72369 72380	carboplatin
T2089	indication 72554 72569	Prostate Cancer
T2091	tradename 72595 72603	TAXOTERE
T2093	indication 72621 72636	prostate cancer
T2095	tradename 72734 72742	TAXOTERE
T2097	dose 72743 72750	75 mg/m
T2099	frequency 72751 72764	every 3 weeks
T2101	co-administereddrug 72785 72795	prednisone
T2103	dose 72796 72800	5 mg
T2105	routeofadministration 72801 72807	orally
T2107	frequency 72808 72819	twice daily
T2109	indication 72971 72986	Prostate Cancer
T2111	tradename 73000 73008	TAXOTERE
T2113	co-administereddrug 73029 73039	Prednisone
T2115	tradename 73049 73057	TAXOTERE
T2117	dose 73058 73066	75 mg/m2
T2119	frequency 73078 73091	every 3 weeks
T2121	co-administereddrug 73094 73104	prednisone
T2123	dose 73105 73109	5 mg
T2125	frequency 73110 73121	twice daily
T2127	dose 73154 73162	12 mg/m2
T2129	frequency 73163 73176	every 3 weeks
T2131	dose 73190 73194	5 mg
T2133	frequency 73195 73206	twice daily
T2135	adversereaction 73293 73299	Anemia
T2137	adversereaction 73310 73321	Neutropenia
T2139	adversereaction 73334 73350	Thrombocytopenia
T2141	adversereaction 73359 73378	Febrile neutropenia
T2143	adversereaction 73391 73400	Infection
T2145	adversereaction 73411 73420	Epistaxis
T2147	adversereaction 73429 73447	Allergic Reactions
T2149	adversereaction 73456 73503	Fluid Retention* Weight Gain* Peripheral Edema*
T2151	adversereaction 73638 73655	Rash/Desquamation
T2153	adversereaction 73687 73699	Nail Changes
T2155	adversereaction 73709 73715	Nausea
T2157	adversereaction 73726 73734	Diarrhea
T2159	adversereaction 73745 73767	Stomatitis/Pharyngitis
T2161	tradename 73799 73807	TAXOTERE
T2163	dose 73808 73816	75 mg/m2
T2165	frequency 73817 73830	every 3 weeks
T2167	co-administereddrug 73833 73843	prednisone
T2169	dose 73844 73848	5 mg
T2171	frequency 73849 73860	twice daily
T2173	dose 73893 73901	12 mg/m2
T2175	frequency 73902 73915	every 3 weeks
T2177	dose 73929 73933	5 mg
T2179	frequency 73934 73945	twice daily
T2181	adversereaction 74032 74049	Taste Disturbance
T2183	adversereaction 74059 74067	Vomiting
T2185	adversereaction 74078 74086	Anorexia
T2187	adversereaction 74097 74102	Cough
T2189	adversereaction 74112 74119	Dyspnea
T2191	adversereaction 74129 74162	Cardiac left ventricular function
T2193	adversereaction 74184 74191	Fatigue
T2195	adversereaction 74202 74209	Myalgia
T2197	adversereaction 74220 74227	Tearing
T2199	adversereaction 74237 74247	Arthralgia
T2201	tradename 74340 74348	TAXOTERE
T2203	indication 74352 74374	gastric adenocarcinoma
T2205	indication 74461 74483	gastric adenocarcinoma
T2207	tradename 74565 74573	TAXOTERE
T2209	dose 74574 74582	75 mg/m2
T2211	co-administereddrug 74603 74612	cisplatin
T2213	co-administereddrug 74617 74629	fluorouracil
T2215	indication 74795 74809	Gastric Cancer
T2217	tradename 74838 74846	TAXOTERE
T2219	dose 74847 74855	75 mg/m2
T2221	co-administereddrug 74858 74867	cisplatin
T2223	dose 74868 74876	75 mg/m2
T2225	co-administereddrug 74890 74902	fluorouracil
T2227	dose 74903 74912	750 mg/m2
T2229	dose 74940 74949	100 mg/m2
T2231	dose 74965 74975	1000 mg/m2
T2233	adversereaction 75101 75107	Anemia
T2235	adversereaction 75120 75131	Neutropenia
T2237	adversereaction 75144 75149	Fever
T2239	adversereaction 75210 75226	Thrombocytopenia
T2241	adversereaction 75238 75247	Infection
T2243	adversereaction 75260 75279	Febrile neutropenia
T2245	tradename 75315 75323	TAXOTERE
T2247	dose 75324 75332	75 mg/m2
T2249	co-administereddrug 75335 75344	cisplatin
T2251	dose 75345 75353	75 mg/m2
T2253	co-administereddrug 75367 75379	fluorouracil
T2255	dose 75380 75389	750 mg/m2
T2257	dose 75417 75426	100 mg/m2
T2259	dose 75442 75452	1000 mg/m2
T2261	adversereaction 75578 75599	Neutropenic infection
T2263	adversereaction 75614 75632	Allergic reactions
T2265	adversereaction 75642 75658	Fluid retention*
T2267	adversereaction 75668 75674	Edema*
T2269	adversereaction 75747 75756	Dizziness
T2271	adversereaction 75766 75774	Alopecia
T2273	adversereaction 75785 75794	Rash/itch
T2275	adversereaction 75804 75816	Nail changes
T2277	adversereaction 75851 75857	Nausea
T2279	adversereaction 75870 75878	Vomiting
T2281	adversereaction 75891 75899	Anorexia
T2283	adversereaction 75912 75922	Stomatitis
T2285	adversereaction 75935 75943	Diarrhea
T2287	adversereaction 75955 75967	Constipation
T2289	adversereaction 75978 76012	Esophagitis/dysphagia/ odynophagia
T2291	adversereaction 76045 76075	Gastrointestinal pain/cramping
T2293	adversereaction 76107 76127	Cardiac dysrhythmias
T2295	adversereaction 76136 76155	Myocardial ischemia
T2297	adversereaction 76164 76171	Tearing
T2299	adversereaction 76180 76195	Altered hearing
T2301	indication 76411 76431	Head and Neck Cancer
T2303	tradename 76457 76465	TAXOTERE
T2305	indication 76469 76489	head and neck cancer
T2307	tradename 76591 76599	TAXOTERE
T2309	dose 76600 76608	75 mg/m2
T2311	co-administereddrug 76629 76638	cisplatin
T2313	co-administereddrug 76643 76655	fluorouracil
T2315	indication 76976 76981	SCCHN
T2317	tradename 77020 77028	TAXOTERE
T2319	co-administereddrug 77049 77058	cisplatin
T2321	co-administereddrug 77063 77075	fluorouracil
T2323	tradename 77203 77211	TAXOTERE
T2325	tradename 77269 77277	TAXOTERE
T2327	adversereaction 77540 77551	Neutropenia
T2329	adversereaction 77576 77582	Anemia
T2331	adversereaction 77606 77622	Thrombocytopenia
T2333	adversereaction 77645 77654	Infection
T2335	adversereaction 77675 77695	Febrile neutropenia*
T2337	adversereaction 77721 77742	Neutropenic infection
T2339	adversereaction 77769 77780	Cancer pain
T2341	adversereaction 77802 77810	Lethargy
T2343	adversereaction 77832 77837	Fever
T2345	adversereaction 77897 77904	Myalgia
T2347	adversereaction 77922 77933	Weight loss
T2349	adversereaction 77954 77961	Allergy
T2351	adversereaction 77978 77994	Fluid retention*
T2353	adversereaction 77996 78001	Edema
T2355	adversereaction 78007 78018	Weight gain
T2357	adversereaction 78176 78185	Dizziness
T2359	adversereaction 78237 78252	Altered hearing
T2361	adversereaction 78300 78308	Alopecia
T2363	adversereaction 78330 78339	Rash/itch
T2365	adversereaction 78359 78367	Dry skin
T2367	adversereaction 78384 78396	Desquamation
T2369	adversereaction 78413 78419	Nausea
T2371	adversereaction 78442 78452	Stomatitis
T2373	adversereaction 78476 78484	Vomiting
T2375	adversereaction 78506 78514	Diarrhea
T2377	adversereaction 78535 78547	Constipation
T2379	adversereaction 78568 78576	Anorexia
T2381	adversereaction 78599 78633	Esophagitis/dysphagia/ Odynophagia
T2383	tradename 78732 78740	TAXOTERE
T2385	tradename 78798 78806	TAXOTERE
T2387	adversereaction 79069 79074	Taste
T2389	adversereaction 79076 79098	sense of smell altered
T2391	adversereaction 79129 79159	Gastrointestinal pain/cramping
T2393	adversereaction 79189 79198	Heartburn
T2395	adversereaction 79217 79242	Gastrointestinal bleeding
T2397	adversereaction 79270 79289	Cardiac dysrhythmia
T2399	adversereaction 79332 79351	Ischemia myocardial
T2401	adversereaction 79368 79375	Tearing
T2403	adversereaction 79392 79406	Conjunctivitis
T2405	adversereaction 79548 79568	Febrile neutropenia:
T2407	adversereaction 79587 79592	fever
T2409	adversereaction 79610 79629	grade 4 neutropenia
T2411	routeofadministration 79640 79651	intravenous
T2413	adversereaction 80151 80163	diffuse pain
T2415	adversereaction 80165 80175	chest pain
T2417	adversereaction 80177 80205	radiation recall phenomenon.
T2419	adversereaction 80233 80252	atrial fibrillation
T2421	adversereaction 80254 80274	deep vein thrombosis
T2423	adversereaction 80276 80293	ECG abnormalities
T2425	adversereaction 80295 80311	thrombophlebitis
T2427	adversereaction 80313 80331	pulmonary embolism
T2429	adversereaction 80333 80340	syncope
T2431	adversereaction 80342 80353	tachycardia
T2433	adversereaction 80355 80377	myocardial infarction.
T2435	adversereaction 80419 80448	cutaneous lupus erythematosus
T2437	adversereaction 80467 80484	bullous eruptions
T2439	adversereaction 80493 80512	erythema multiforme
T2441	adversereaction 80514 80538	Stevens-Johnson syndrome
T2443	adversereaction 80540 80566	toxic epidermal necrolysis
T2445	adversereaction 80572 80596	Scleroderma-like changes
T2447	adversereaction 80617 80639	peripheral lymphedema.
T2449	adversereaction 80747 80769	hand and foot syndrome
T2451	adversereaction 80829 80843	abdominal pain
T2453	adversereaction 80845 80853	anorexia
T2455	adversereaction 80855 80867	constipation
T2457	adversereaction 80869 80883	duodenal ulcer
T2459	adversereaction 80885 80896	esophagitis
T2461	adversereaction 80898 80925	gastrointestinal hemorrhage
T2463	adversereaction 80927 80955	gastrointestinal perforation
T2465	adversereaction 80957 80973	ischemic colitis
T2467	adversereaction 80975 80982	colitis
T2469	adversereaction 80984 81006	intestinal obstruction
T2471	adversereaction 81008 81013	ileus
T2473	adversereaction 81015 81040	neutropenic enterocolitis
T2475	adversereaction 81156 81220	bleeding episodes. Disseminated intravascular coagulation (DIC)
T2477	adversereaction 81248 81254	sepsis
T2479	adversereaction 81258 81276	multiorgan failure
T2481	adversereaction 81307 81329	acute myeloid leukemia
T2483	adversereaction 81334 81357	myelodysplasic syndrome
T2485	tradename 81397 81405	TAXOTERE
T2487	adversereaction 81537 81555	anaphylactic shock
T2489	adversereaction 81713 81722	hepatitis
T2491	adversereaction 81851 81860	confusion
T2493	adversereaction 81876 81884	seizures
T2495	adversereaction 81888 81919	transient loss of consciousness
T2497	adversereaction 82020 82034	conjunctivitis
T2499	adversereaction 82036 82047	lacrimation
T2501	adversereaction 82106 82123	Excessive tearing
T2503	adversereaction 82224 82253	transient visual disturbances
T2505	adversereaction 82255 82262	flashes
T2507	adversereaction 82264 82279	flashing lights
T2509	adversereaction 82281 82291	scotomata)
T2511	adversereaction 82357 82383	hypersensitivity reactions
T2513	adversereaction 82495 82522	cystoid macular edema (CME)
T2515	tradename 82567 82576	TAXOTERE.
T2517	adversereaction 82622 82633	ototoxicity
T2519	adversereaction 82635 82652	hearing disorders
T2521	adversereaction 82660 82672	hearing loss
T2523	adversereaction 82780 82801	acute pulmonary edema
T2525	adversereaction 82803 82850	acute respiratory distress syndrome/pneumonitis
T2527	adversereaction 82852 82877	interstitial lung disease
T2529	adversereaction 82879 82901	interstitial pneumonia
T2531	adversereaction 82903 82922	respiratory failure
T2533	adversereaction 82928 82946	pulmonary fibrosis
T2535	adversereaction 83040 83061	radiation pneumonitis
T2537	adversereaction 83158 83177	renal insufficiency
T2539	adversereaction 83182 83195	renal failure
T2541	adversereaction 83352 83364	hyponatremia
T2543	activeingredient 83439 83448	Docetaxel
T2545	activeingredient 83534 83543	docetaxel
T2547	activeingredient 83738 83747	docetaxel
T2549	activeingredient 83918 83928	docetaxel.
T2551	tradename 83959 83967	TAXOTERE
T2553	activeingredient 84023 84032	docetaxel
T2555	tradename 84104 84112	TAXOTERE
T2557	tradename 84150 84158	TAXOTERE
T2559	tradename 84562 84570	TAXOTERE
T2561	tradename 84645 84653	TAXOTERE
T2563	tradename 84919 84928	TAXOTERE.
T2565	tradename 84951 84959	TAXOTERE
T2567	dose 85073 85100	&#x2030; 0.3 and 0.03 mg/kg
T2569	frequency 85100 85104	/day
T2571	tradename 85266 85274	TAXOTERE
T2573	activeingredient 85566 85575	docetaxel
T2575	tradename 85744 85752	TAXOTERE
T2577	tradename 85975 85983	TAXOTERE
T2579	tradename 86122 86130	TAXOTERE
T2581	tradename 86253 86261	TAXOTERE
T2583	tradename 86391 86399	TAXOTERE
T2585	co-administereddrug 86525 86534	cisplatin
T2587	co-administereddrug 86539 86559	5-fluoruracil (TCF).
T2589	tradename 86582 86590	TAXOTERE
T2591	tradename 86603 86611	TAXOTERE
T2593	dose 86815 86824	125 mg/m2
T2595	routeofadministration 86837 86848	intravenous
T2597	frequency 86858 86872	every 21 days.
T2599	adversereaction 86922 86934	neutropenia.
T2601	tradename 86982 86990	TAXOTERE
T2603	tradename 87480 87488	TAXOTERE
T2605	tradename 87504 87512	TAXOTERE
T2607	co-administereddrug 87545 87554	cisplatin
T2609	co-administereddrug 87559 87579	5-fluorouracil (TCF)
T2611	tradename 87845 87853	TAXOTERE
T2613	dose 87855 87863	75 mg/m)
T2615	co-administereddrug 87884 87893	cisplatin
T2617	dose 87895 87903	75 mg/m)
T2619	co-administereddrug 87908 87922	5-fluorouracil
T2621	dose 87924 87933	750 mg/m)
T2623	dose 87957 87965	80 mg/m)
T2625	dose 87986 87995	1000 mg/m
T2627	frequency 87995 88000	/day)
T2629	activeingredient 88314 88323	docetaxel
T2631	activeingredient 88396 88405	docetaxel
T2633	dose 88424 88432	55 mg/m2
T2635	dose 88436 88445	235 mg/m2
T2637	routeofadministration 88458 88469	intravenous
T2639	frequency 88490 88503	every 3 weeks
T2641	activeingredient 88557 88566	docetaxel
T2643	clearance 88592 88608	17.3 10.9 L/h/m2
T2645	activeingredient 88633 88642	Docetaxel
T2647	co-administereddrug 88680 88689	cisplatin
T2649	co-administereddrug 88694 88714	5-fluorouracil (TCF)
T2651	dose 88734 88742	75 mg/m2
T2653	routeofadministration 88755 88766	intravenous
T2655	activeingredient 88880 88889	Docetaxel
T2657	clearance 88904 88920	17.9 8.75 L/h/m2
T2659	auc 88950 88968	4.20 2.57 g.h/mL.
T2661	activeingredient 89036 89045	docetaxel
T2663	indication 89456 89482	Non-Small Cell Lung Cancer
T2665	indication 89540 89545	NSCLC
T2667	tradename 89582 89591	TAXOTERE+
T2669	co-administereddrug 89591 89600	cisplatin
T2671	tradename 89751 89760	TAXOTERE+
T2673	co-administereddrug 89760 89769	cisplatin
T2675	tradename 90047 90056	TAXOTERE+
T2677	co-administereddrug 90056 90065	cisplatin
T2679	adversereaction 90067 90075	diarrhea
T2681	adversereaction 90083 90099	peripheral edema
T2683	adversereaction 90110 90120	stomatitis
T2685	tradename 90284 90293	TAXOTERE+
T2687	co-administereddrug 90293 90302	cisplatin
T2689	adversereaction 90370 90378	diarrhea
T2691	adversereaction 90386 90396	infections
T2693	adversereaction 90404 90420	peripheral edema
T2695	adversereaction 90431 90441	stomatitis
T2697	tradename 90591 90599	TAXOTERE
T2699	co-administereddrug 90618 90629	carboplatin
T2701	indication 90671 90709	advanced non-small cell lung carcinoma
T2703	tradename 90837 90846	TAXOTERE+
T2705	co-administereddrug 90846 90855	cisplatin
T2707	adversereaction 90883 90891	diarrhea
T2709	adversereaction 90893 90902	infection
T2711	adversereaction 90907 90923	peripheral edema
T2713	indication 91004 91019	Prostate Cancer
T2715	tradename 91053 91061	TAXOTERE
T2717	frequency 91062 91079	every three weeks
T2719	co-administereddrug 91085 91095	prednisone
T2721	indication 91103 91118	prostate cancer
T2723	tradename 91258 91266	TAXOTERE
T2725	frequency 91267 91284	every three weeks
T2727	adversereaction 91445 91451	anemia
T2729	adversereaction 91467 91476	infection
T2731	adversereaction 91492 91504	nail changes
T2733	adversereaction 91520 91528	anorexia
T2735	adversereaction 91544 91555	weight loss
T2737	indication 91605 91618	Breast Cancer
T2739	indication 91635 91648	breast cancer
T2741	tradename 91665 91673	TAXOTERE
T2743	co-administereddrug 91694 91705	doxorubicin
T2745	co-administereddrug 91710 91726	cyclophosphamide
T2747	indication 92023 92037	Gastric Cancer
T2749	tradename 92074 92082	TAXOTERE
T2751	co-administereddrug 92103 92112	cisplatin
T2753	co-administereddrug 92117 92129	fluorouracil
T2755	indication 92137 92151	gastric cancer
T2757	adversereaction 92621 92629	lethargy
T2759	adversereaction 92631 92641	stomatitis
T2761	adversereaction 92643 92651	diarrhea
T2763	adversereaction 92653 92662	dizziness
T2765	adversereaction 92664 92669	edema
T2767	adversereaction 92671 92712	febrile neutropenia/neutropenic infection
T2769	indication 92914 92934	Head and Neck Cancer
T2771	tradename 93008 93016	TAXOTERE
T2773	co-administereddrug 93037 93046	cisplatin
T2775	co-administereddrug 93051 93063	fluorouracil
T2777	indication 93074 93079	SCCHN
T2779	tradename 93245 93253	TAXOTERE
T2781	co-administereddrug 93274 93283	cisplatin
T2783	co-administereddrug 93288 93300	fluorouracil
T2785	indication 93318 93323	SCCHN
T2787	tradename 93720 93729	TAXOTERE.
T2789	tradename 93861 93869	TAXOTERE
T2791	tradename 93998 94006	TAXOTERE
T2793	tradename 94210 94218	TAXOTERE
T2795	adversereaction 94422 94445	bone marrow suppression
T2797	adversereaction 94447 94471	peripheral neurotoxicity
T2799	adversereaction 94477 94487	mucositis.
T2801	dose 94739 94748	150 mg/m2
T2803	dose 94772 94781	200 mg/m2
T2805	adversereaction 94840 94858	severe neutropenia
T2807	adversereaction 94860 94873	mild asthenia
T2809	adversereaction 94875 94894	cutaneous reactions
T2811	adversereaction 94900 94916	mild paresthesia
T2813	routeofadministration 95021 95032	intravenous
T2815	dose 95059 95068	154 mg/kg
T2817	dose 95104 95113	100 mg/m2
T2819	dose 95251 95259	48 mg/kg
T2821	dose 95295 95304	100 mg/m2
T2823	dose 95385 95393	20 mg/kg
T2825	dose 95427 95436	100 mg/m2
T2827	activeingredient 95577 95586	Docetaxel
T2829	activeingredient 95808 95817	docetaxel
T2831	activeingredient 95987 95996	Docetaxel
T2833	activeingredient 96046 96055	Docetaxel
T2835	molecularweight 96173 96179	861.9.
T2837	tradename 96282 96290	TAXOTERE
T2839	tradename 96314 96322	TAXOTERE
T2841	activeingredient 96324 96334	docetaxel)
T2843	activeingredient 96498 96507	docetaxel
T2845	inactiveingredient 96534 96548	polysorbate 80
T2847	inactiveingredient 96576 96594	dehydrated alcohol
T2849	tradename 96627 96635	TAXOTERE
T2851	activeingredient 96709 96718	docetaxel
T2853	tradename 96765 96773	TAXOTERE
T2855	activeingredient 97000 97009	Docetaxel
T2857	activeingredient 97171 97180	Docetaxel
T2859	activeingredient 97509 97520	Docetaxel's
T2861	activeingredient 97790 97799	docetaxel
T2863	dose 97863 97871	20 mg/m2
T2865	dose 97875 97884	115 mg/m2
T2867	dose 97988 97996	70 mg/m2
T2869	dose 98000 98009	115 mg/m2
T2871	activeingredient 98047 98058	Docetaxel's
T2873	clearance 98260 98269	21 L/h/m2
T2875	activeingredient 98468 98477	docetaxel
T2877	volumeofdistribution 98567 98573	113 L.
T2879	activeingredient 98614 98623	docetaxel
T2881	activeingredient 98886 98896	docetaxel.
T2883	activeingredient 98980 98989	docetaxel
T2885	activeingredient 99256 99265	docetaxel
T2887	activeingredient 99306 99315	Docetaxel
T2889	tradename 99905 99913	TAXOTERE
T2891	dose 99949 99959	100 mg/m2.
T2893	activeingredient 100106 100115	docetaxel
T2895	activeingredient 100310 100320	docetaxel.
T2897	tradename 101005 101014	TAXOTERE.
T2899	dose 101273 101281	10 mg/m2
T2901	dose 101285 101293	90 mg/m2
T2903	dose 101356 101365	100 mg/m2
T2905	activeingredient 101426 101435	docetaxel
T2907	activeingredient 101589 101598	docetaxel
T2909	activeingredient 101692 101701	docetaxel
T2911	dose 101703 101711	100 mg/m
T2913	routeofadministration 101712 101724	intravenous)
T2915	activeingredient 101734 101743	docetaxel
T2917	dose 101745 101752	10 mg/m
T2919	routeofadministration 101753 101765	intravenous)
T2921	dose 101800 101806	200 mg
T2923	routeofadministration 101807 101813	orally
T2925	frequency 101814 101836	once daily for 3 days)
T2927	activeingredient 101972 101981	docetaxel
T2929	activeingredient 102047 102056	docetaxel
T2931	activeingredient 102254 102263	Docetaxel
T2933	activeingredient 102389 102398	docetaxel
T2935	activeingredient 102504 102514	docetaxel.
T2937	activeingredient 102595 102604	docetaxel
T2939	activeingredient 102743 102752	docetaxel
T2941	activeingredient 103056 103065	docetaxel
T2943	activeingredient 103172 103181	docetaxel
T2945	indication 103303 103316	breast cancer
T2947	activeingredient 103379 103388	docetaxel
T2949	dose 103390 103398	75 mg/m)
T2951	dose 103413 103421	50 mg/m)
T2953	dose 103445 103454	500 mg/m)
T2955	activeingredient 103524 103533	docetaxel
T2957	activeingredient 103800 103809	docetaxel
T2959	activeingredient 103906 103915	docetaxel
T2961	activeingredient 104074 104083	docetaxel
T2963	activeingredient 104131 104140	Docetaxel
T2965	dose 104283 104301	0.39 to 1.56 mg/kg
T2967	activeingredient 104383 104392	Docetaxel
T2969	activeingredient 104478 104487	Docetaxel
T2971	routeofadministration 104551 104562	intravenous
T2973	dose 104578 104587	0.3 mg/kg
T2975	routeofadministration 104884 104895	intravenous
T2977	dose 104905 104912	5 mg/kg
T2979	dose 104925 104936	0.375 mg/kg
T2981	indication 105217 105230	Breast Cancer
T2983	tradename 105269 105277	TAXOTERE
T2985	indication 105301 105345	locally advanced or metastatic breast cancer
T2987	tradename 105632 105640	TAXOTERE
T2989	dose 105642 105651	100 mg/m2
T2991	frequency 105652 105666	every 3 weeks)
T2993	dose 105700 105708	12 mg/m2
T2995	frequency 105709 105723	every 6 weeks)
T2997	dose 105741 105748	6 mg/m2
T2999	frequency 105749 105763	every 3 weeks)
T3001	tradename 105822 105830	TAXOTERE
T3003	tradename 105967 105975	TAXOTERE
T3005	tradename 106309 106317	TAXOTERE
T3007	indication 106338 106351	Breast Cancer
T3009	activeingredient 106478 106487	Docetaxel
T3011	activeingredient 106691 106701	Docetaxel:
T3013	activeingredient 106903 106913	Docetaxel:
T3015	activeingredient 107175 107185	docetaxel.
T3017	tradename 107336 107344	TAXOTERE
T3019	dose 107346 107356	100 mg/m2)
T3021	dose 107373 107382	75 mg/m2)
T3023	frequency 107383 107397	every 3 weeks.
T3025	tradename 107459 107467	TAXOTERE
T3027	tradename 107908 107916	TAXOTERE
T3029	indication 107937 107950	Breast Cancer
T3031	activeingredient 108074 108083	Docetaxel
T3033	activeingredient 108255 108265	Docetaxel:
T3035	activeingredient 108456 108466	Docetaxel:
T3037	activeingredient 108725 108735	docetaxel.
T3039	indication 108863 108876	breast cancer
T3041	tradename 108982 108990	TAXOTERE
T3043	dose 109003 109011	60 mg/m2
T3045	dose 109021 109029	75 mg/m2
T3047	dose 109041 109050	100 mg/m2
T3049	tradename 109257 109265	TAXOTERE
T3051	dose 109327 109335	75 mg/m2
T3053	dose 109354 109363	100 mg/m2
T3055	dose 109404 109412	60 mg/m2
T3057	dose 109417 109426	100 mg/m2
T3059	tradename 109516 109524	TAXOTERE
T3061	dose 109538 109547	100 mg/m2
T3063	indication 109625 109649	metastatic breast cancer
T3065	indication 109757 109770	breast cancer
T3067	tradename 110105 110113	TAXOTERE
T3069	dose 110181 110189	60 mg/m2
T3071	indication 110248 110293	locally advanced or metastatic breast cancer.
T3073	dose 110490 110499	100 mg/m2
T3075	indication 110551 110564	Breast Cancer
T3077	tradename 110666 110674	TAXOTERE
T3079	indication 110742 110755	breast cancer
T3081	tradename 110942 110950	TAXOTERE
T3083	dose 110951 110959	75 mg/m2
T3085	co-administereddrug 110986 110997	doxorubicin
T3087	dose 110998 111006	50 mg/m2
T3089	co-administereddrug 111011 111027	cyclophosphamide
T3091	dose 111028 111037	500 mg/m2
T3093	dose 111064 111072	50 mg/m2
T3095	dose 111098 111107	500 mg/m2
T3097	dose 111130 111139	500 mg/m2
T3099	frequency 111183 111210	every 3 weeks for 6 cycles.
T3101	tradename 111212 111220	TAXOTERE
T3103	routeofadministration 111290 111301	intravenous
T3105	co-administereddrug 111452 111461	tamoxifen
T3107	dose 111462 111467	20 mg
T3109	frequency 111468 111492	daily for up to 5 years.
T3111	activeingredient 111814 111834	docetaxel-containing
T3113	indication 113388 113401	Breast Cancer
T3115	indication 114167 114201	Non-Small Cell Lung Cancer (NSCLC)
T3117	tradename 114240 114248	TAXOTERE
T3119	indication 114330 114356	non-small cell lung cancer
T3121	tradename 114498 114506	TAXOTERE
T3123	tradename 114622 114630	TAXOTERE
T3125	dose 114639 114647	75 mg/m2
T3127	tradename 114782 114790	TAXOTERE
T3129	dose 114804 114813	100 mg/m2
T3131	adversereaction 114857 114877	hematologic toxicity
T3133	adversereaction 114879 114889	infections
T3135	adversereaction 114913 114922	mortality
T3137	indication 115140 115166	non-small cell lung cancer
T3139	tradename 115293 115301	TAXOTERE
T3141	tradename 115435 115443	TAXOTERE
T3143	dose 115444 115453	100 mg/m2
T3145	adversereaction 115489 115501	toxic deaths
T3147	tradename 115542 115550	TAXOTERE
T3149	dose 115551 115560	75 mg/m2.
T3151	tradename 115644 115652	TAXOTERE
T3153	dose 115653 115661	75 mg/m2
T3155	indication 115797 115823	non-small cell lung cancer
T3157	tradename 115935 115943	TAXOTERE
T3159	dose 115944 115952	75 mg/m2
T3161	tradename 115955 115963	TAXOTERE
T3163	dose 115964 115973	100 mg/m2
T3165	dose 116041 116049	30 mg/m2
T3167	frequency 116077 116090	every 3 weeks
T3169	dose 116105 116111	2 g/m2
T3171	frequency 116130 116144	every 3 weeks.
T3173	tradename 116342 116350	TAXOTERE
T3175	dose 116351 116359	75 mg/m2
T3177	tradename 116529 116537	TAXOTERE
T3179	indication 116558 116584	Non-Small Cell Lung Cancer
T3181	activeingredient 116752 116761	Docetaxel
T3183	dose 116762 116770	75 mg/m2
T3185	activeingredient 116846 116855	Docetaxel
T3187	dose 116856 116864	75 mg/m2
T3189	activeingredient 117019 117029	Docetaxel:
T3191	activeingredient 117939 117948	docetaxel
T3193	tradename 118189 118197	TAXOTERE
T3195	dose 118198 118206	75 mg/m2
T3197	tradename 118271 118279	TAXOTERE
T3199	dose 118280 118288	75 mg/m2
T3201	tradename 118376 118384	TAXOTERE
T3203	dose 118385 118393	75 mg/m2
T3205	tradename 118476 118484	TAXOTERE
T3207	dose 118498 118506	75 mg/m2
T3209	tradename 118664 118672	TAXOTERE
T3211	indication 118696 118701	NSCLC
T3213	indication 118794 118799	NSCLC
T3215	tradename 118889 118897	TAXOTERE
T3217	dose 118898 118906	75 mg/m2
T3219	co-administereddrug 118952 118961	cisplatin
T3221	dose 118962 118970	75 mg/m2
T3223	frequency 118993 119006	every 3 weeks
T3225	dose 119020 119028	25 mg/m2
T3227	dose 119103 119112	100 mg/m2
T3229	frequency 119154 119167	every 4 weeks
T3231	tradename 119189 119197	TAXOTERE
T3233	co-administereddrug 119202 119214	carboplatin.
T3235	tradename 119315 119324	TAXOTERE+
T3237	co-administereddrug 119324 119333	cisplatin
T3239	tradename 119596 119604	TAXOTERE
T3241	co-administereddrug 119608 119617	cisplatin
T3243	tradename 120072 120081	TAXOTERE+
T3245	co-administereddrug 120081 120090	cisplatin
T3247	tradename 120200 120208	TAXOTERE
T3249	indication 120266 120271	NSCLC
T3251	tradename 120305 120314	Taxotere+
T3253	co-administereddrug 120314 120323	Cisplatin
T3255	tradename 120590 120599	TAXOTERE+
T3257	co-administereddrug 120599 120608	cisplatin
T3259	tradename 120651 120660	TAXOTERE+
T3261	co-administereddrug 120660 120669	cisplatin
T3263	tradename 120753 120762	TAXOTERE+
T3265	co-administereddrug 120762 120771	cisplatin
T3267	tradename 120989 120998	TAXOTERE+
T3269	co-administereddrug 120998 121009	carboplatin
T3271	tradename 121069 121077	TAXOTERE
T3273	tradename 121143 121152	TAXOTERE+
T3275	co-administereddrug 121152 121163	carboplatin
T3277	tradename 121230 121239	TAXOTERE+
T3279	co-administereddrug 121239 121250	carboplatin
T3281	tradename 121527 121536	TAXOTERE+
T3283	co-administereddrug 121536 121545	cisplatin
T3285	tradename 121698 121706	TAXOTERE
T3287	tradename 121790 121799	TAXOTERE+
T3289	co-administereddrug 121799 121808	Cisplatin
T3291	indication 122209 122243	Hormone Refractory Prostate Cancer
T3293	tradename 122282 122290	TAXOTERE
T3295	co-administereddrug 122311 122321	prednisone
T3297	indication 122339 122407	androgen independent (hormone refractory) metastatic prostate cancer
T3299	tradename 122624 122632	TAXOTERE
T3301	dose 122633 122641	75 mg/m2
T3303	frequency 122642 122655	every 3 weeks
T3305	tradename 122682 122690	TAXOTERE
T3307	dose 122691 122699	30 mg/m2
T3309	frequency 122713 122719	weekly
T3311	dose 122798 122806	12 mg/m2
T3313	frequency 122807 122820	every 3 weeks
T3315	dose 122911 122915	5 mg
T3317	frequency 122916 122927	twice daily
T3319	tradename 122961 122969	TAXOTERE
T3321	frequency 122970 122986	every three week
T3323	tradename 123108 123116	TAXOTERE
T3325	tradename 123254 123262	TAXOTERE
T3327	frequency 123263 123275	every 3 week
T3329	tradename 123389 123397	TAXOTERE
T3331	indication 123432 123500	Androgen Independent (Hormone Refractory) Metastatic Prostate Cancer
T3333	tradename 123539 123548	TAXOTERE+
T3335	co-administereddrug 123549 123559	Prednisone
T3337	frequency 123560 123573	every 3 weeks
T3339	frequency 123610 123623	every 3 weeks
T3341	indication 124358 124380	Gastric Adenocarcinoma
T3343	tradename 124489 124497	TAXOTERE
T3345	indication 124542 124564	gastric adenocarcinoma
T3347	indication 124576 124623	adenocarcinoma of the gastroesophageal junction
T3349	tradename 124764 124772	TAXOTERE
T3351	dose 124778 124786	75 mg/m2
T3353	co-administereddrug 124817 124826	cisplatin
T3355	dose 124832 124840	75 mg/m2
T3357	co-administereddrug 124855 124867	fluorouracil
T3359	dose 124873 124882	750 mg/m2
T3361	frequency 124883 124902	per day for 5 days)
T3363	dose 124917 124926	100 mg/m2
T3365	dose 124955 124965	1000 mg/m2
T3367	frequency 124966 124985	per day for 5 days)
T3369	tradename 126278 126286	TAXOTERE
T3371	indication 126321 126343	gastric adenocarcinoma
T3373	tradename 126931 126939	TAXOTERE
T3375	indication 127067 127081	Gastric Cancer
T3377	indication 127451 127465	Gastric Cancer
T3379	indication 127870 127890	Head and Neck Cancer
T3381	tradename 127986 127994	TAXOTERE
T3383	indication 128039 128091	squamous cell carcinoma of the head and neck (SCCHN)
T3385	indication 128236 128241	SCCHN
T3387	tradename 128340 128348	TAXOTERE
T3389	tradename 128362 128370	TAXOTERE
T3391	dose 128375 128383	75 mg/m2
T3393	co-administereddrug 128396 128405	cisplatin
T3395	dose 128410 128418	75 mg/m2
T3397	co-administereddrug 128441 128453	fluorouracil
T3399	dose 128458 128467	750 mg/m2
T3401	frequency 128539 128570	every three weeks for 4 cycles.
T3403	dose 128752 128761	100 mg/m2
T3405	dose 128801 128812	1000 mg/m2/
T3407	frequency 128889 128920	every three weeks for 4 cycles.
T3409	dose 129355 129368	1.8 Gy-2.0 Gy
T3411	frequency 129369 129379	once a day
T3413	frequency 129381 129396	5 days per week
T3415	dose 129417 129429	66 to 70 Gy)
T3417	frequency 129480 129491	twice a day
T3419	dose 129580 129591	70 to 74 Gy
T3421	tradename 130290 130298	TAXOTERE
T3423	indication 130371 130376	SCCHN
T3425	tradename 130424 130433	TAXOTERE+
T3427	co-administereddrug 130434 130444	Cisplatin+
T3429	co-administereddrug 130456 130468	Fluorouracil
T3431	tradename 131241 131250	TAXOTERE+
T3433	co-administereddrug 131250 131272	Cisplatin+Fluorouracil
T3435	tradename 132295 132303	TAXOTERE
T3437	indication 132422 132427	SCCHN
T3439	indication 132561 132566	SCCHN
T3441	tradename 132682 132690	TAXOTERE
T3443	tradename 132704 132712	TAXOTERE
T3445	dose 132717 132724	75 mg/m
T3447	routeofadministration 132728 132739	intravenous
T3449	dose 132784 132792	100 mg/m
T3451	routeofadministration 132835 132846	intravenous
T3453	routeofadministration 132884 132895	intravenous
T3455	dose 132925 132934	1000 mg/m
T3457	frequency 132934 132938	/day
T3459	frequency 132996 133023	every 3 weeks for 3 cycles.
T3461	dose 133090 133098	100 mg/m
T3463	routeofadministration 133128 133139	intravenous
T3465	routeofadministration 133185 133196	intravenous
T3467	dose 133226 133235	1000 mg/m
T3469	frequency 133235 133239	/day
T3471	frequency 133297 133324	every 3 weeks for 3 cycles.
T3473	routeofadministration 133626 133637	intravenous
T3475	dose 133767 133771	2 Gy
T3477	frequency 133772 133779	per day
T3479	frequency 133781 133808	5 days per week for 7 weeks
T3481	dose 133829 133838	70-72 Gy)
T3483	tradename 134077 134096	TAXOTERE-containing
T3485	tradename 134361 134369	TAXOTERE
T3487	tradename 134517 134526	TAXOTERE+
T3489	co-administereddrug 134527 134550	Cisplatin+ Fluorouracil
T3491	tradename 134842 134851	TAXOTERE+
T3493	co-administereddrug 134851 134873	cisplatin+fluorouracil
T3495	tradename 136461 136469	TAXOTERE
T3497	tradename 136505 136513	TAXOTERE
T3499	tradename 136630 136638	TAXOTERE
T3501	tradename 136666 136674	TAXOTERE
T3503	activeingredient 136676 136686	docetaxel)
T3505	activeingredient 136727 136736	docetaxel
T3507	inactiveingredient 136777 136811	polysorbate 80/dehydrated alcohol.
T3509	tradename 136889 136897	TAXOTERE
T3511	tradename 136928 136936	TAXOTERE
T3513	activeingredient 136938 136948	docetaxel)
T3515	activeingredient 136989 136998	docetaxel
T3517	inactiveingredient 137036 137070	polysorbate 80/dehydrated alcohol.
T3519	tradename 137663 137671	TAXOTERE
T3521	tradename 137858 137866	TAXOTERE
T3523	tradename 138038 138046	TAXOTERE
T3525	routeofadministration 138114 138118	oral
T3527	adversereaction 138380 138406	hypersensitivity reaction.
T3529	adversereaction 138465 138480	fluid retention
T3531	adversereaction 138489 138505	peripheral edema
T3533	adversereaction 138532 138543	weight gain
T3535	adversereaction 138548 138556	dyspnea.
T3537	adversereaction 138809 138816	myalgia
T3539	tradename 138943 138951	TAXOTERE
T3541	tradename 139116 139124	TAXOTERE
T3543	adversereaction 139303 139309	nausea
T3545	adversereaction 139311 139319	vomiting
T3547	adversereaction 139321 139329	diarrhea
T3549	adversereaction 139331 139343	constipation
T3551	adversereaction 139345 139352	fatigue
T3553	adversereaction 139354 139371	excessive tearing
T3555	adversereaction 139373 139396	infusion site reactions
T3557	adversereaction 139402 139411	hair loss
T3559	activeingredient 139432 139441	docetaxel
T3561	tradename 139511 139519	TAXOTERE
T3563	activeingredient 139534 139544	docetaxel)
T3565	routeofadministration 139578 139589	Intravenous
T3567	tradename 139685 139693	TAXOTERE
T3569	tradename 139972 139981	TAXOTERE?
T3571	tradename 139993 140001	TAXOTERE
T3573	adversereaction 140044 140050	death.
T3575	adversereaction 140090 140095	death
T3577	tradename 140118 140126	TAXOTERE
T3579	tradename 140209 140217	TAXOTERE
T3581	indication 140234 140260	non-small cell lung cancer
T3583	tradename 140368 140376	TAXOTERE
T3585	tradename 140470 140479	TAXOTERE.
T3587	tradename 140644 140652	TAXOTERE
T3589	tradename 140936 140945	TAXOTERE.
T3591	adversereaction 141000 141006	fever.
T3593	adversereaction 141040 141058	allergic reactions
T3595	tradename 141089 141098	TAXOTERE.
T3597	adversereaction 141119 141137	allergic reactions
T3599	adversereaction 141570 141586	fluid retention)
T3601	tradename 141609 141618	TAXOTERE.
T3603	co-administereddrug 141749 141763	corticosteroid
T3605	tradename 141777 141785	TAXOTERE
T3607	co-administereddrug 141827 141841	corticosteroid
T3609	tradename 141926 141934	TAXOTERE
T3611	co-administereddrug 141971 141985	corticosteroid
T3613	tradename 142054 142063	TAXOTERE?
T3615	tradename 142075 142083	TAXOTERE
T3617	indication 142169 142182	breast cancer
T3619	indication 142194 142220	non-small cell lung cancer
T3621	indication 142232 142247	prostate cancer
T3623	indication 142260 142274	stomach cancer
T3625	indication 142286 142306	head and neck cancer
T3627	tradename 142337 142345	TAXOTERE
T3629	tradename 142406 142415	TAXOTERE?
T3631	tradename 142442 142450	TAXOTERE
T3633	tradename 142559 142567	TAXOTERE
T3635	inactiveingredient 142605 142620	polysorbate 80.
T3637	tradename 142770 142779	TAXOTERE?
T3639	tradename 142953 142962	TAXOTERE?
T3641	tradename 142993 143001	TAXOTERE
T3643	tradename 143099 143108	TAXOTERE?
T3645	tradename 143186 143195	TAXOTERE.
T3647	tradename 143314 143322	TAXOTERE
T3649	tradename 143433 143441	TAXOTERE
T3651	tradename 143538 143546	TAXOTERE
T3653	tradename 143724 143732	TAXOTERE
T3655	tradename 143835 143843	TAXOTERE
T3657	tradename 144017 144026	TAXOTERE?
T3659	tradename 144039 144047	TAXOTERE
T3661	routeofadministration 144075 144091	intravenous (IV)
T3663	tradename 144150 144158	TAXOTERE
T3665	frequency 144176 144190	every 3 weeks.
T3667	tradename 144267 144276	TAXOTERE.
T3669	tradename 144383 144391	TAXOTERE
T3671	tradename 144421 144430	TAXOTERE.
T3673	tradename 144602 144611	TAXOTERE.
T3675	tradename 144661 144670	TAXOTERE?
T3677	tradename 144682 144690	TAXOTERE
T3679	tradename 144814 144823	TAXOTERE?
T3681	adversereaction 144836 144864	Acute Myeloid Leukemia (AML)
T3683	tradename 144920 144928	TAXOTERE
T3685	tradename 145113 145122	TAXOTERE.
T3687	adversereaction 145159 145201	redness and swelling of your arms and legs
T3689	adversereaction 145207 145228	peeling of your skin.
T3691	adversereaction 145270 145278	numbness
T3693	adversereaction 145280 145288	tingling
T3695	adversereaction 145290 145324	or burning in your hands and feet.
T3697	adversereaction 145362 145376	blurred vision
T3699	adversereaction 145380 145395	loss of vision.
T3701	tradename 145408 145416	TAXOTERE
T3703	tradename 145468 145476	TAXOTERE
T3705	tradename 145559 145567	TAXOTERE
T3707	tradename 145700 145708	TAXOTERE
T3709	tradename 145773 145781	TAXOTERE
T3711	adversereaction 145802 145832	changes in your sense of taste
T3713	adversereaction 145852 145867	short of breath
T3715	adversereaction 145879 145891	constipation
T3717	adversereaction 145903 145921	decreased appetite
T3719	adversereaction 145933 145972	changes in your fingernails or toenails
T3721	adversereaction 145984 146006	swelling of your hands
T3723	adversereaction 146008 146020	face or feet
T3725	adversereaction 146033 146054	feeling weak or tired
T3727	adversereaction 146067 146088	joint and muscle pain
T3729	adversereaction 146101 146107	nausea
T3731	adversereaction 146112 146120	vomiting
T3733	adversereaction 146133 146141	diarrhea
T3735	adversereaction 146153 146172	mouth or lips sores
T3737	adversereaction 146184 146193	hair loss
T3739	adversereaction 146206 146210	rash
T3741	adversereaction 146223 146241	redness of the eye
T3743	adversereaction 146243 146257	excess tearing
T3745	adversereaction 146270 146284	skin reactions
T3747	tradename 146300 146308	TAXOTERE
T3749	tradename 146451 146459	TAXOTERE
T3751	tradename 146651 146660	TAXOTERE.
T3753	tradename 146895 146903	TAXOTERE
T3755	tradename 147113 147122	TAXOTERE.
T3757	tradename 147265 147273	TAXOTERE
T3759	tradename 147420 147429	TAXOTERE?
T3761	activeingredient 147471 147480	docetaxel
T3763	inactiveingredient 147511 147518	ethanol
T3765	inactiveingredient 147523 147537	polysorbate 80
T3767	frequency 147549 147565	Every three-week
T3769	tradename 147579 147587	TAXOTERE
T3771	indication 147592 147598	breast
T3773	indication 147600 147631	non-small cell lung and stomach
T3775	indication 147633 147658	and head and neck cancers
T3777	routeofadministration 147669 147673	oral
T3779	co-administereddrug 147674 147688	corticosteroid
T3781	routeofadministration 147735 147739	Oral
T3783	co-administereddrug 147740 147754	corticosteroid
T3785	tradename 147866 147874	TAXOTERE
T3787	frequency 147952 147968	Every three-week
T3789	tradename 147982 147990	TAXOTERE
T3791	indication 147995 148010	prostate cancer
T3793	routeofadministration 148021 148025	oral
T3795	co-administereddrug 148026 148040	corticosteroid
T3797	routeofadministration 148098 148102	Oral
T3799	co-administereddrug 148103 148117	corticosteroid
T3801	tradename 148203 148211	TAXOTERE
T3803	company 148358 148381	sanofi-aventis U.S. LLC
T3805	company 148406 148420	SANOFI COMPANY
T3807	company 148465 148488	sanofi-aventis U.S. LLC
